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Despite long-term research efforts to identify a cohesive explanation of racial disparities in
cancer outcomes, evidence remains mixed. Disparities persist in randomized clinical trials,
suggesting that inherited factors contribute to differential outcomes. Hemoglobin variants
represent a heretofore unstudied inherited prognostic factor, the most prevalent of which is sickle
cell trait (SCT). SCT is disproportionally prevalent in African American/Blacks (AA/Bs) (~8%)
compared to non-Hispanic whites (NHWs) (<0.1%). Case report evidence suggests SCT interacts
with the tumor microenvironment and rigors of cancer treatment, inducing adverse outcomes.
We identified 162,357 older cancer patients (75,633 breast; 86,904 prostate) diagnosed 20072013 using the SEER-Medicare linked database. AA/B and NHW patients were grouped by
hemoglobinopathy status (AA/B+, AA/B-, NHW-) and three-way propensity score weighting
was performed to evaluate treatment completion, occurrence of adverse events, and survival. A
total of 371 AA/B+ patients were analyzed, compared to 17,303 AA/B- and 144,863 NHW-. At
diagnosis, AA/B+ were more likely than AA/B- and NHW- to have multiple comorbidities
including cerebrovascular disease, diabetes, and chronic renal failure. After propensity score
weighting, no significant association was observed in treatment completion status between
AA/B+ and AA/B-. Among treated patients, however, AA/B+ status was associated with
increased risk of experiencing one or more adverse event compared to both AA/B- (HR: 1.15,
95% CI: 1.07 – 1.24) and NHW- (HR: 1.18, 95% CI: 1.10 – 1.26). While hazards models failed
to reveal significant differences across study groups, the magnitude of the associations with

Jessica R Hoag – University of Connecticut, 2017
mortality in relation to either treatment completion or adverse events varied by
hemoglobinopathy status. Among AA/B+ who completed treatment, those who experienced one
or more adverse events had more than five times the mortality risk compared to those with no
adverse events (HR: 5.56, 95% CI: 4.70 – 6.58) whereas the estimated mortality risk among
AA/B- and NHW- patients were approximately three-fold. Among patients who failed to
complete treatment, however, the adverse event-mortality relationship was similar across groups.
This study, to our knowledge, provides the first analytical evidence of SCT and other
hemoglobinopathies as prognostic biomarkers in cancer, acting as important effect modifiers of
the association between treatment completion, adverse events, and mortality.
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1.0 Introduction
1.1 Background
1.1.1 Racial disparities in cancer outcomes
Cancer is the leading cause of death in the United States (US) among men and women
ages 40-79 and the second-leading cause of death in the US overall, accounting for 23% of all
deaths and over 550,000 deaths annually.1 Compared to non-Hispanic Whites (NHW), the
African American/Black (AA/B) population experiences 22.3% and 12.6% higher all-site cancer
mortality rates for men and women, respectively; AA/B women are 40% more likely to die from
breast cancer than NHW women in the US, and AA/B men are more than twice as likely to die
from prostate cancer than NHW men.1 Despite the steady decline in cancer mortality rates since
the 1990s in all groups, largely attributed to the introduction of improved cancer therapies and
screening techniques2, racial disparities persist.3 The largest racial disparities in cancer-specific
mortality have persisted for over three decades within breast and prostate cancer, the two most
prevalent cancers among AA/B women and men, respectively.3 Further, the survival gap has
increased between AA/B and NHW breast cancer patients1,3, hence, novel questions are
warranted.4
Established and putative explanatory factors of racial disparities in cancer outcomes
reflect a complex interplay across three major domains5: 1) macroenvironment level; 2)
individual environment level; and, 3) biologic levels such as cellular biomarkers and inherited
genetic variants.5 Applying this multilevel approach to disparities research for cancer outcomes
has highlighted interactions among and between macroenvironment factors such as geography
and latent discriminatory policies and practices that reduce access to and completion of high
quality cancer care with local/individual factors such as socioeconomic deprivation,
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comorbidities, and lower rates of healthcare utilization.6-8 Despite an extensive body of research
documenting these contributions to outcome disparities, a composite analysis of randomized
clinical trials (RCTs) from the Southwest Oncology Group (SWOG) reported that racial
disparities in breast and prostate cancer survival remained after controlling for clinical
presentation (e.g., stage, histology, and tumor characteristics) among patients with similar
eligibility requirements who received uniform therapy.9 These findings suggest that unmeasured
factors, such as genetic status, may be associated with persistent outcome disparities.10
Specifically, our current investigation focuses on the prognostic role of a prevalent
inherited genotype in the AA/B population, sickle cell trait (SCT), which to date has not been the
object of a systematic investigation in cancer outcomes. This topic was prompted by a recent
report of multiple cases with SCT and sickle cell disease (SCD) who experienced various
adverse events during systemic chemotherapy or whose tumors exhibited increased hypoxia.11
SCT is the most common genetic mutation of hemoglobin worldwide; in the US, the prevalence
of SCT is comparatively high in the AA/B population at 8.0% compared to < 1.0% of NHWs.12
Additional hemoglobinopathies are included in this investigation as described later.
SWOG findings also could be explained by residual confounding due to differences in
tumor clinicopathology. For example, in an analysis of 373,563 women diagnosed with invasive
breast cancer from 2004 to 2011 in the Surveillance, Epidemiology, and End Results (SEER) 18
registries database, AA/B women with small tumors (less than or equal to 2 cm) were more
likely to present with lymph node metastases (24.1% vs. 18.4%, respectively, p < .001) and
distant metastases (1.5% vs. 1.0%, respectively, p < .001) compared to NHW women.13
Population-based gene expression profiling of intrinsic breast cancer subtypes has revealed a
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much higher prevalence of aggressive basal-likei tumors among premenopausal AA/B woman
compared to postmenopausal AA/B and non-AA/B women of all ages, and a lower prevalence of
less aggressive luminal Aii tumors.14 In spite of these differences, however, the incidence of more
aggressive tumor subtypes has not accounted for worse breast-cancer specific survival in AA/B
women compared to NHW women, particularly among women with stage I disease.13,14
Further, evidence from an RCT examining long-term follow-up of adjuvant taxane therapy in
approximately 5,000 (8% AA/B) women with stage II and III breast cancer suggested that even
among patients with more favorable ER positive disease, AA/B women were at higher risk of
recurrence and experienced worse overall survival after adjustment for obesity, disease stage,
and treatment adherence.15 Since AA/B women diagnosed with breast cancer exhibit greater
intratumor genetic heterogeneity compared to NHW women, it could be that overall genomic
instability, epigenetic changes, or some other inherited influence(s) are contributing more
aggressive and/or treatment resistant disease.16 Whether the presence of SCT or other inherited
hemoglobinopathies play a role in tumor metastasis and treatment resistance is unknown.
Studies of genetic variation in drug metabolizing genes across populations have reported
reduced cancer survival17 in relation to certain genotypes, and can serve as a general model for
studying the impact of SCT and other inherited hemoglobinopathies on clinical outcomes.18
Adverse drug responses may materialize as lower tumor response rates and increased systemic
toxicity, which can lead to non-standard dose adjustments, treatment discontinuation, and worse
survival. For example, hematologic toxicity (i.e. leukopenia and anemia) from chemotherapeutic
antimetabolites such as 5-fluorouracil (5-FU) is significantly more prevalent in AA/B patients

i

ii

Basal-like: estrogen receptor (ER) negative, progesterone receptor (PR) negative, human epidermal growth factor receptor-2 (HER2) negative,
cytokeratin 5/6 positive, and/or HER1 positive.
Luminal A: ER positive and/or PR positive, HER2 negative.
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compared to NHWs, likely attributable to higher prevalence of dihydropyrimidine
dehydrogenase (DPD)iii deficiency (8% in AA/B compared to 2.8% in NHW).18,19 DPD
deficiency is thought to be the result of germline polymorphisms in a host of genes with greater
population frequencies in AA/Bs compared to NHWs and other genetic ancestries. Other
chemotherapeutic adverse drug responses that could be due to differences in genetic ancestry and
are more likely among AA/B compared to NHW include cardiotoxicity from anthracyclines18,20,
cisplatin-induced nephrotoxicity, and lower maximum tolerable dose.20,21 Predicted adverse
events related to SCT and other hemoglobinopathies are discussed in detail in section 1.1.4, and
the biologic plausibility is proposed in section 1.1.5.
Despite the documented history of racial disparities in cancer outcomes in the US and
evidence for distinct chemotherapy-related toxicities between AA/B and NHW cancer patients,
there is no available research outside of a collection of case reports regarding the impact of
inherited hemoglobinopathies on cancer related adverse drug response and outcomes.11 In a
secondary analysis of the large SEER-Medicare claims database, we will evaluate if there is an
association between sickling hemoglobinopathies and adverse events in cancer patients and if
these events contribute to racial disparities in cancer survival.

1.1.2 Epidemiology of hemoglobinopathies: Sickle cell trait and sickle cell anemia
Sickling hemoglobinopathies are the result of mutations that occur in the beta globin
gene, one component of the hemoglobin (Hb) protein.22 SCT (commonly abbreviated HbAS) is a
monogenic inherited heterozygous single base pair substitution (p.Glu7Val, rs334) in the Beta
globin (HBB) gene on chromosome 11. Red blood cells (RBCs) of SCT carriers generally

iii

DPD is the rate-limiting enzyme of 5-FU catabolism18,19
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contain 35-40% abnormal hemoglobin (HbS), but this proportion is not static either within or
between individuals with SCT.22-24 SCT is prevalent in approximately 1 in 12 (8%) AA/B in the
US and the incidence of SCT is 25 times higher in AA/B compared to NHW, and 10 times
higher compared to Hispanics.12 Sickle cell anemia (SCA, commonly abbreviated HbSS) is the
most common genetic disorder of SCD and occurs through homozygous inheritance of the
p.Glu7Val mutation in HBB. SCD has an estimated prevalence of approximately 1 in 365 AA/B
in the US, compared to approximately 1 in 16,000 Hispanics, and less than 0.1% in the NHW
population.25 For individuals with SCD, conditions of either local or systemic deoxygenation can
cause abnormal beta globin to polymerize hemoglobin within RBCs thus disturbing RBC shape
and ease of circulation with a propensity to adhere to the endothelium.22

1.1.3 Epidemiology of hemoglobinopathies: Thalassemia disorders
Thalassemia disorders and associated variants in the US are characterized by mutations in
either alpha or beta globin genes that result in reduced or absent production of hemoglobin. The
prevalence of thalassemia in the US is increasing and is driven primarily by increased
immigration from affected regions in Asia and Arab countries.26,27 Among newborns screened in
California, the prevalence of the beta-thalassemia variant Hb H represents over 80% of
thalassemic conditions.26 Similarly, Hb E (the second most common hemoglobin variant in the
world after SCT28) is often co-inherited with Hb H and is most commonly prevalent among
individuals from Cambodian and Thai/Laotian ancestry, respectively.29 Thalassemia disorders
are prevalent around the world with estimated ranges from 5 to 40% across Western Africa, the
Eastern Mediterranean, Middle East, and Southeast Asia.30
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1.1.4 Clinical complications associated with hemoglobinopathies
Clinical manifestations of SCD are a consequence of the accumulation of rigid sickled
RBCs that adhere to the vascular endothelium and obstruct blood flow, triggering both hemolysis
and vaso-occulsive “sickling crises” from tissue hypoxia, enhanced apoptosis, tissue necrosis,
and organ damage.22 Complications of sickling crises include severe intermittent pain,
susceptibility to infection, stroke, organ failure, and early death.31 Historically, SCT has been
considered a benign condition that confers a protective effect against malaria, but recent
evidence suggests that SCT may be related to numerous health conditions.32 In addition to
exercise-related sudden death, some adverse health complications associated with SCT include
renal medullary carcinoma, hematuria, renal papillary necrosis, hyposthenuria, splenic infarction,
and exertional rhabdomyolysis.33,34 Known factors associated with rare but clinically significant
adverse outcomes include hypoxemia, acidosis, and dehydration; most of which are often
encountered during periods of intense exercise, under extreme heat, or at high altitudes.35 The
proposed pathophysiological mechanisms through which individuals with SCT experience
exertional injury and death include slight decrease in RBC deformability, increase of whole
blood viscosity, oxidative stress, and systematic inflammation.36 It should be noted, however,
that the magnitude of these responses is less than that observed among individuals with SCA.36
Recent large observational cohort studies have revealed additional adverse associations
with SCT. For example, a cross-sectional analysis across four dialysis centers in three North
Carolina counties found that SCT was twice as common among AA/B with end-stage renal
disease (ESRD) compared with the general AA/B population (15% vs. 7%, p<0.001).37
Subsequently, Naik et al. (2014), in a pooled analysis of 15,000 AA/B from five populationbased cohorts found a positive association between SCT and chronic kidney disease (CKD)
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within each cohort.38 Another prospective study of AA/B adults (mean age of SCT carriers: 53;
SD: 6) found a positive association between SCT and stroke, with increased risk observed after
controlling for demographics and traditional cerebrovascular risk factors.39 In a prospective
cohort of AA/B followed from 1987 through 2011 in the Atherosclerosis Risk in Communities
Study, the adjusted hazard ratios of venous thromboembolism and pulmonary embolism were
1.50 (95% CI: 0.96 – 2.36) and 2.05 (95% CI: 1.12 – 3.76), respectively, for participants with
SCT compared to those without SCT.40 The characterization of adverse events associated with
SCT continues to evolve, with a focus on impact on morbidity as well as clinical mechanisms of
disease.
In contrast to sickling hemoglobinopathies, the range of different clinical phenotypes
represented in thalassemia disorders is less heterogeneous; the most common complication of
both alpha- and beta-thalassemia is anemia with or without evidence of hemolysis.22 Individuals
with only one deletion of the four alpha-globin genes generally do not exhibit any adverse
clinical phenotype; individuals with two alpha-globin deletions, however, may experience
anemia without hemolysis. Serious complications of thalassemias include infection, osteoporosis,
and heart and liver disease due to iron overload from receipt of regular blood transfusions.41 The
presence of alpha thalassemia in individuals with SCT has been shown to modify the
concentration of sickle hemoglobin in RBCs and exacerbate ischemic-reperfusion injury leading
to renal disease.42 More recently, renal dysfunction in patients with thalassemia without
concomitant SCT or SCA has been documented, posited to be caused by hypoxia, anemia and
iron-mediated toxicity.43,44 In a sample of 216 individuals primarily presenting with variants of
beta thalassemia, Quinn et al. (2011) documented albuminuria in 59% of patients, as well as
renal hyperfiltration and hypercalciuria in approximately one-third of patients.45
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1.1.5 Biologic plausibility underlying hemoglobinopathies and cancer outcomes
We posit that the mechanisms that trigger sickling and vaso-occlusion in individuals with
SCD may be responsible for similar processes, at both the tumor and systemic levels, in SCT
carriers undergoing cancer therapy. In SCD, conditions of low oxygen in the blood (i.e.,
hypoxia) play a central role in the cycle of RBC deoxygenation and sickling, as well as the
promotion of inflammation and angiogenesis.46,47 For example, despite a lack of systematic
population-based studies, both animal and case-report evidence suggest that provocation of RBC
sickling within or near the tumor microenvironment among cancer patients with SCT may be
related to hypoxia, an adverse tumor feature found in 50-60% of locally advanced solid
tumors.11,48,49 At the systemic level, a putative mechanism for hypoxic-related induction of
sickling in the SCT patient with cancer may be the physiologic rigors of systemic chemotherapy,
general anesthesia admitted during surgery, and local radiotherapy 11,48-51
It is biologically plausible that RBC sickling is associated with hypoxia and subsequent
angiogenesis in the tumor microenvironment, resulting in tumor progression and/or reduced
sensitivity to systemic chemotherapy. In the tumor microenvironment, hypoxia can be caused by
inadequate blood flow in tissues, an increase in diffusion distances with tumor expansion, and
reduced oxygen transport capacity of the blood subsequent to anemia.52 Under these conditions,
hypoxia inducible factors (HIFs) accumulate and activate genes that express protein products
related to oxygen delivery, angiogenesis, and glycolysis—all of which are related to an increase
in tumor cell survival, growth, and metastasis.52 In analysis of 40 patients ages 5 to 32 with renal
medullary carcinoma (RMC), a hypoxic tumor found almost exclusively in young patients with
SCT, Swartz et al. found diffuse expression of HIF and vascular endothelial growth factor
(VEGF), a key protein involved in angiogenesis.53
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In addition to promoting tumor growth and metastasis, hypoxia is also related to direct
and indirect resistance to radiotherapy and chemotherapy.54 First, many anticancer drugs exhibit
decreased cytotoxicity at low oxygen concentrations and are therefore less effective within a
hypoxic tumor microenvironment.55 Second, hypoxia promotes proliferation of cells with
diminished apoptotic potential, specifically those with p53 mutations.56 Third, poor blood flow
associated with an impaired vasculature can lead to diminished distribution of chemotherapeutic
agents into the tumor.55
In individuals with either SCD or SCT, the molecular mechanism through which
resistance to malaria occurs is thought to involve a higher rate of heme release from sickled
versus normal hemoglobin57 which might be of relevance to tumoral hypoxia. Free heme induces
heme oxygenase-1 (HO-1), responsible for the oxidative degradation of cellular heme.58 HO-1
overexpression is prevalent in many solid tumors and is associated with reduced sensitivity to
chemotherapy, advanced disease stage, and poor prognosis.58,59 Promoted by overexpression of
HO-1, murine melanoma models with SCD experienced accelerated tumor angiogenesis, tumor
growth, and metastatic potential three weeks after melanoma tumor inoculation compared to wild
type mice.60 In addition, tumors from SCD mice were marked by frequent microvascular
occlusion. Terman et al. (2013) demonstrated rapid adherence of sickled RBCs but not normal
RBCs to tumor vasculature, also characterized by vaso-occulsion.61
In addition to plausible interactions between hemoglobinopathies and the hypoxic tumor
microenvironment leading to adverse outcomes in cancer, associations between
hemoglobinopathies and sub-clinical or clinical comorbid conditions such as renal dysfunction
and chronic kidney disease may interact to induce adverse cancer outcomes. In individuals with
SCD, hypoxia-induced sickling in the renal medulla results in a dose-dependent relationship with

9

kidney injury in the form of glomeruloscleriosis and proteinuria.38,62 Naik et al. (2014) observed
approximately 6% of incident chronic kidney disease was attributable to SCT, with additional
associations with decline in estimated glomerular filtration rate (eGFR), and albuminuria.38
Among individuals with transfusion-independent beta-thalassemia, renal dysfunction and disease
can develop via anemia and increased intestinal iron absorption triggered by ineffective
erythropoiesis. Chronic hypoxia of tubular cells lead to endothelial and epithelial injury,
glomerulosclerosis, kidney fibrosis, and an ultimate decline in eGFR.43,44 In cancer patients,
acute renal failure and chronic kidney disease are associated with survival in patients with
cancer, through limited ability to withstand aggressive therapies due to dose adjustments in
chemotherapeutic agents excreted primarily by the kidneys.63,64
Overall, we hypothesize that the increased physiologic stressors, specifically sustained
tumor hypoxia and sickling events, in cancer patients with inherited hemoglobinopathies, is
positively associated with a more malignant cancer phenotype and treatment resistance,
potentially leading to lower rates of treatment completion, increased rates of adverse events, and
worse overall survival.

1.1.6 SCT and public health research agenda
A 2010 workshop of The National Heart, Lung, and Blood Institute (NHLBI) of the NIH
as well as a 2009 working meeting of CDC via request from the Sickle Cell Disease Association
of America have provided information and guidelines regarding health implications of SCT, gaps
in current public health research, and frameworks for future research initiatives.32 Similarly, the
American Society of Hematology (ASH) recently published a set of sickle cell research priorities
which included unanswered questions regarding the contribution of SCT to health outcomes.65
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From a historical perspective, early efforts to conduct sickle cell screening were marred by issues
of discrimination, stigma, and poor or inadequate counseling.32 In the early 1970s, race-based
newborn screening programs were instituted in 34 US states, targeting AA/B individuals
exclusively. In 1981, a young woman in North Carolina brought a federal case against the local
Burke County Health Department and Department of Social Services after being erroneously
diagnosed with SCT during a prenatal care visit and coerced to undergo unwanted sterilization.66
In other instances, individuals with SCT were denied health and life insurance, faced
employment discrimination, and denied entry into the armed forces.67,68 A lack of public
awareness combined with inconsistent health education programs persists into the present and
may often result in messages delivered to SCT carriers and their families that increase stigma
and anxiety.32 Since 2010, the National Collegiate Athletic Association (NCAA) has required all
athletes at Division I and II schools to be tested (with an ‘opt-out’ provision for students who can
show proof of a prior test or who are willing to sign a waiver of liability) for SCT.69 The NCAA
has worked with the American College of Sports Medicine (ACSM) to formulate guidelines and
establish a research agenda to study the relationship between physical exertion and SCT, but
organizations such as ASH have publicly opposed the testing and disclosure of SCT status,
instead recommending universal interventions for all athletes to reduce exertion-related injury
and death, following policy implemented by the US Army.70
Despite the controversy surrounding SCT screening among athletes, universal newborn
screening for hemoglobinopathies regardless of race has been mandated in all 50 states and the
District of Columbia since May 1, 2006.71 Beginning with New York in 1975, other states
gradually adopted universal screening for hemoglobinopathies, but variation continues to exist in
the types of hemoglobinopathies screened for, the techniques used for screening, and the
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counseling offered to families. No standardized medical language ontology or data collection
techniques are integrated across states, and only New York, Texas, Washington, and California
perform molecular testing as a routine part of their screening protocols.71,72 The staggered and
non-uniform implementation of universal screening for hemoglobinopathies has resulted an
estimated 84% of the adult population with SCT and other hemoglobinopathy variants currently
unaware of their status.73-76 Further, only an estimated 37% of families are notified of SCT from
newborn screening follow-up, likely due to the fact that many screening programs have no
protocols for ensuring positive results for SCT are received.76
Even with the advent of adequate genetic counseling programs, the dearth of information
available regarding the potential health consequences of SCT will still leave families uncertain
about best health practices. The NIH, CDC, and ASH have all highlighted the issue of limited
population-based research assessing adverse health outcomes associated with SCT, and have
recommended studies that employ databases with sufficient population size to analyze these
associations.77 From the perspective of cancer outcomes research, it may be appropriate for
investigations to include all hemoglobinopathies in addition to SCT, since it is possible that
mechanisms leading to adverse cancer events in patients with SCT may be similar for other
hemoglobin variants.77 One major unanswered question proposed by ASH is whether
hemoglobin variants interact with other genes or gene products to ameliorate or worsen other
conditions65, which can be practically appended to the challenge in cancer therapeutics research
in determining whether SCT or other hemoglobin variants interact with specific oncogenic
mutations or exhibit response within malignant tumor environments.
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1.2 Preliminary Research
The absence of population-based studies among individuals with hemoglobinopathies has
made it difficult to confidently predict associations with cancer outcomes. In addition to a
published collection of case reports documenting an association between SCT and cancer
outcomes11, Dr. Swede conducted a chart review on a sample of 94 breast cancer patients from
the Connecticut Tumor Registry (CTR).
We identified 14 breast cancer patients (12 AA/B versus 2 NHW cases) (1998-2013)
(ICD-9 codes: 174.x; ICD-O-3 codes: C50.0–C50.9) about whom also was reported a status of
SCT or SCD (ICD-9 codes: 282.5, 282.60, 282.61, 282.62, 282.63, 282.64, 282.68, 282.69) from
the Yale-New Haven Hospital system (including the Hospital of Saint Raphael) in Connecticut.
An age- and race-matched sample of breast cancer patients without a report of sickling
hemoglobinopathy diagnosis (n = 40 AA/B and n = 40 NHW controls) also was identified.
Demographic and clinical information was abstracted from each patient’s medical chart,
including medical history.78 Breast surgery, radiation, and chemotherapy regimens, as well as
any complications/adverse events related to each treatment also were recorded. Adverse events
potentially related to SCT were defined as one or more of the following: mild joint pain (diffuse
or specific), severe joint pain (diffuse or specific), renal insufficiency, renal failure, deep vein
thrombosis, cerebrovascular event (stroke), emergency room visit, hospitalization, and early
treatment discontinuation.79,80
Median follow-up was shorter for AA/B SCT+ cases (46 months) compared to AA/B
SCT- controls (88 months) and NHW SCT- controls (99 months). Five of 14 SCT+ cases died
during follow-up (35.7%), compared to 32.5% (n = 13) for AA/B SCT- controls and 15.0% (n =
6) for NHW SCT- controls. Of the 5 SCT+ cases who died, the cause of death was associated
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with sickle cell disorder for only 1 patient. A summary of demographic and clinical
characteristics is provided in Table 1.1. Since this preliminary investigation did not have
sufficient power to detect true differences if they exist between groups of patients, statistical tests
of significance were not performed. The proportion of AA/B women who experienced at least
one adverse event from any treatment (surgery, radiation, chemotherapy) was similar between
SCT+ and SCT- patients (64.3% and 63.2%, respectively) and nearly 50% higher than in NHW
SCT- patients (35.9%), as seen in Figure 1.1.
A comparison of complications by treatment modality (surgery, radiation, and
chemotherapy) suggest that a higher proportion of AA/B SCT+ breast cancer patients undergoing
surgery, radiation, or chemotherapy, respectively, experienced adverse events compared to AA/B
SCT- and NHW SCT- patients. Of the 12 AA/B SCT+ patients who had surgery, 58.3% (n = 7)
experienced one or more adverse event, of which 1 was potentially associated with SCT. Of the
38 AA/B SCT- patients who had surgery, 31.6% (n = 12) experienced one or more adverse
event, of which 2 were potentially associated with SCT. Of the 38 NHW SCT- patients who had
surgery, 15.8% (n = 6) experienced one or more adverse event, none of which were potentially
associated with SCT.
Of the six AA/B SCT+ that had radiation therapy, 83.3% (n = 5) experienced one or more
adverse event. Of the 29 AA/B SCT- patients that had radiation therapy, 37.9% (n = 11)
experienced one or more adverse event (Table 1.2). Of the 25 NHW SCT- that had radiation
therapy, 12.0% (n = 3) experienced one or more adverse event. No patients experienced an
adverse event potentially associated with SCT. Of the 8 AA/B SCT+ patients who had
chemotherapy, 75.0% (n = 6) experienced one or more adverse event, of which 4 were
potentially associated with SCT. Of the 29 AA/B SCT- patients who had chemotherapy, 58.6%
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(n = 17) experienced one or more adverse event, of which 3 were potentially associated with
SCT. Of the 22 NHW SCT- patients who had chemotherapy, 31.8% (n = 7) experienced one or
more adverse event, 1 of which was potentially associated with SCT. The potential sicklingrelated adverse events experienced following surgery and chemotherapy were hospitalization,
treatment discontinuation, joint pain, and deep vein thrombosis (AA/B SCT+ only, n = 2).
Overall, a descriptive presentation of results suggests that SCT+ breast cancer patients
experience a larger proportion of potentially unique complications that carry with them clinical
implications for treatment protocols.
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1.3 Research Plan
1.3.1 Conceptual model
Based on the biologic plausibility of an association between SCT (and potentially other
hemoglobinopathies) and adverse cancer outcomes, our conceptual model proposes an increase
in tumor hypoxia among patients with SCT who are diagnosed with cancer. The sustained tumor
hypoxia resulting from the cycle of RBC deoxygenation and sickling is positively associated
with an aggressive tumor phenotype and resistance to radiation and chemotherapy, ultimately
leading to lower rates of treatment completion, increased adverse events, and worse survival
(Figure 1.2).

1.3.2 Specific Aims
In a sample of AA/B patients diagnosed with breast (female only) or prostate cancer
with diagnosed hemoglobinopathies (AA/B +, n= 371) and a propensity score-weighted sample
of patients without diagnosed hemoglobinopathies (AA/B -, n= 17,303; NHW-, n= 144,863), we
pursued the following primary analyses:

Aim 1. Describe demographic and clinical characteristics of the three study groups (AA/B+,
AA/B-, NHW-) such as age, comorbidities, AJCC 6th edition stage, histology, survival time, and
treatment received by cancer site (breast, prostate).

Aim 2. Compare treatment completion (yes/no) across the three study groups by cancer site
(breast, prostate) and stage.

16

Aim 3. Compare rates of specific adverse events (e.g., hospitalization, neutropenia, acute renal
dysfunction, anemia, deep vein thrombosis, joint pain, cardiotoxicity) across the three patient
groups after receipt of treatment.

Aim 4. Estimate differences in survival across the three patient groups (all-cause, site-specific,
and competing-risk mortality).

2.0 Methods
2.1 Database
We used patient-level information from Medicare claims linked to population-based
cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program of
the National Cancer Institute (NCI). The SEER program collects cancer incidence, vital status,
and clinicopathological data for patients and tumors from 18 geographic registries covering
approximately 28% of the US population, including 26% (n = 9,975,844) of the AA/B
population.81 Contributing to the SEER program are nine states (New Mexico, Hawaii, Utah,
Iowa, Connecticut, Greater California, Kentucky, Louisiana, New Jersey), five metropolitan
areas (Metro Atlanta with a sample of rural Georgia, San Francisco-Oakland and San JoseMonterey, Los Angeles, Seattle, Detroit), and the Alaska Native Tumor Registry. The SEER
program is the gold-standard source of population-based cancer information in the US
comprising patient demographics, clinical and diagnostic information (primary site, morphology,
stage at diagnosis), and survival data.81 Vital status for overall and cause-specific mortality are
reported to SEER by the National Center for Health Statistics.82 Quality control studies
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(casefinding, reabstracting/recoding, reliability studies) are conducted in SEER areas annually
and consistently demonstrate a standard for case ascertainment at 98%.82
Medicare is a federally funded fee-for-service single-payer health insurance program
available to individuals in the US age 65 or older, people under age 65 with certain disabilities,
and people with end-stage renal disease (ESRD).83 As is the case in most analyses of SEERMedicare data, our investigation is limited to the population 65 years or older because the
Medicare population under 65 years is not representative of the general population (only
comprised of disabled individuals and those with ESRD).83 Medicare beneficiaries receive Part
A hospital insurance which helps cover inpatient care and skilled nursing facilities, as well as
hospice and home health care. Most Medicare beneficiaries also receive Part B medical
insurance which helps cover provider services (doctors, nurse practitioners, physical and
occupational therapists) and outpatient care. Part D prescription drug insurance helps cover
prescription drug costs, and Part C (Medicare Advantage Plans) coverage consists of private
health plans (i.e. HMOs) instead of Part A and Part B insurance. All Medicare beneficiaries are
entitled to Part A hospital insurance, but there are monthly premiums associated with Part B and
Part D coverage.84 Original Medicare (Part A and Part B) has existed in some form since 1965,
with the introduction of Part C in 1997, and Part D in 2006.83,84
The linkage between the SEER program and Medicare (SEER-Medicare) is performed by
the NCI and the Centers for Medicare and Medicaid Services (CMS) via matching individual
identifiers (social security number, name, sex, date of birth) in the SEER program to Medicare’s
master enrollment file.83 The linkage has been completed nine times since 1991 and most
recently in 2016. Approximately 93% of people 65 years or older identified in the SEER
program are found in the Medicare enrollment file.83 The full SEER-Medicare database consists
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of multiple files, one of which is SEER program data while the others are Medicare files. Table
2.1 provides an overview of the SEER-Medicare data files requested and used for our research.
The SEER-Medicare database also includes information on a 5% random sample of
Medicare beneficiaries residing in SEER program areas without a diagnosis of cancer to serve as
a control group (SUMDENOM file in Table 2.1). Medicare files are available for this control
group as well as demographic information, and are used in this research to compare comorbidity
profiles in groups with cancer versus those without cancer.83
Since SEER-Medicare data are previously collected and de-identified, The University of
Connecticut Health Institutional Review Board determined that this research did not constitute
human subjects research and was exempt from review.

2.2 Cohort Selection
We identified individuals with a diagnosis of breast (female) or prostate cancer from
2007 to 2013 for inclusion in this investigation. We chose to restrict analysis to breast and
prostate cancer because these cancers are the highest incident cancers in both the AA/B and
NHW populations1 and because they exhibit large and persistent disparities in cancer-specific
mortality between AA/B and NHW patients.3 We included patients for which female breast or
prostate cancer was the first or only primary tumor. For breast cancer patients, we included only
patients with histology consistent with epithelial origin. We included patients age 66 years or
older in order to calculate comorbidities up to one year prior to cancer diagnosis. The cohort was
limited to patients with a known month and year of diagnosis, not diagnosed on an autopsy
report or diagnosis to ensure availability of follow-up information. We also required patients to
have continuous Part A and B coverage from at least one year before through at least one year
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after cancer diagnosis; we excluded patients with HMO coverage because no Medicare claims
are available in the SEER-Medicare database for these patients.83 We constructed three study
groups based on race and a diagnosis of SCT or other hemoglobinopathy:
1. AA/B patients with a hemoglobinopathy diagnosis (AA/B+)
2. AA/B patients with no hemoglobinopathy diagnosis (AA/B-)
3. NHW patients with no hemoglobinopathy diagnosis (NHW-)
The complete cohort selection criteria diagrams for breast and prostate cancer are available in
Appendix A. A total of 163,532 patients met the clinical selection criteria consisting of breast
(female only) (n = 76,135; 46.6%) and prostate cancer (n = 87,397; 62.2%). Of the breast cancer
patients, 6,919 (9.1%) were AA/B and 187 (2.7%) were found to have had at least one claim for
a hemoglobinopathy. Of the prostate cancer patients, 10,755 (12.3%) were AA/B and 184 (1.7%)
had at least one claim for a hemoglobinopathy. A total of 995 NHW patients (n = 502 breast
cancer; n = 493 prostate cancer) with a hemoglobinopathy diagnosis were removed from primary
analyses, but select sensitivity analysis including this group is presented in Appendix D. The
final sample size for the study cohort was 162,537 patients (n = 75,633 breast cancer; n = 86,904
prostate cancer).

2.3 Data Elements
2.3.1 Hemoglobinopathies
We identified patients in the SEER-Medicare database with an International
Classification of Disease (ICD-9) diagnostic code for any hemoglobinopathy (ICD-9: 282.4 –
282.7) over the course of the entire study period (2006-2014) (Table 2.2). A total of 18 distinct
ICD-9 diagnosis codes were identified as hemoglobinopathies, which were further grouped into
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four subcategories: sickle cell trait, sickle cell disease, thalassemia, and other
hemoglobinopathies.

2.3.2 Demographic and clinical covariates
Patient characteristics incorporated into various analyses included: age at diagnosis, race
(AA/B or NHW), year of diagnosis (2007 to 2013), geographic residence (SEER registry area),
urban/rural residence, median household income (measured at the census tract and ZIP code
levels), education (percentage of adults without a high school degree from census tract and ZIP
code levels), marital status (married, single, other), and Charlson Comorbidity Index (CCI)
score85,86 (0, 1, ≥2). Tumor characteristics included in the SEER dataset are: AJCC 6th edition
stage, tumor size (cm), tumor grade (well differentiated, moderately differentiated, poorly
differentiated, undifferentiated), Gleason score (prostate cancer only), histological type (ductal,
lobular, other) (breast cancer only), number of positive lymph nodesiv, estrogen receptor statusv
(breast cancer only), and progesterone receptor statusvi (breast cancer only).
Using a validated macro provided by the NCI, the CCI score was calculated from a
weighted list of 16 conditions based on their respective hazard ratio of death within 1 year of
cancer diagnosis87: myocardial infarction, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, chronic obstructive pulmonary disease, cirrhosis, dementia, paralysis,
diabetes, diabetes with sequelae, chronic renal failure, moderate to severe liver disease,
rheumatologic disease, ulcers, connective tissue disorders, and AIDS. The CCI score is

iv

Collaborative Stage (CS) Regional Nodes Examined
Collaborative Stage (CS) Site-Specific Factor 1
vi
CS Site-Specific Factor 2
v
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calculated based on diagnoses for which associated medical claims appears from one year prior
to cancer diagnosis through one month prior to cancer diagnosis.

2.3.3 Treatment regimen – breast cancervii
A complete list of diagnosis and treatment codes for breast cancer is available in Appendix B.
Surgery
Surgery was defined from Medicare inpatient, outpatient, and carrier claims (ICD-9
procedure codes and HCPCS codes) for mastectomy or breast-conserving surgery (BCS)
(including partial mastectomy or lumpectomy) received within six months of initial diagnosis.

Radiation
Radiation therapy was defined from Medicare outpatient and carrier claims (ICD-9
diagnosis and procedures codes, HCPCS codes, revenue center codes91) for external beam
radiotherapy, intensity modulated radiotherapy, or brachytherapy received within nine months of
initial diagnosis.

Chemotherapy
Chemotherapy was defined from Medicare inpatient, outpatient, carrier, and DME claims
(ICD-9 diagnosis and procedure codes and HCPCS codes). Time to adjuvant chemotherapy was
defined as days from the most definitive resection of the primary site to the first administration
of chemotherapy. Length of adjuvant chemotherapy was defined as the number of months
between the first and last claims indicating the use of chemotherapy, with the standard length

vii

We identified surgery and radiation therapy from both SEER data and Medicare claims 88,89 and identified
chemotherapy from Medicare claims.90
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defined as 24 weeks or six months. For breast cancer patients with estrogen receptor positive and
progesterone receptor positive disease, we also identified the use of hormone therapy using
HCPCS codes.

2.3.4 Treatment regimen – prostate cancer
A complete list of diagnosis and treatment codes for prostate cancer is available in Appendix B.
Surgery
Surgery was defined from Medicare inpatient, outpatient, and carrier claims (ICD-9
procedure codes and HCPCS codes) for prostatectomy, laparoscopic radical prostatectomy with
robotic assistance, with or without pelvic lymph node dissection received within 12 months of
initial diagnosis.

Radiation
Radiation therapy was defined from Medicare outpatient and carrier claims (ICD-9
diagnosis and procedures codes, HCPCS codes, revenue center codes91) for external beam
radiation, brachytherapy, image-guided radiation, stereotactic radiosurgery, or proton beam
radiation therapy received within 12 months of initial diagnosis; for men who received surgery,
receipt of radiation therapy was examined within 12 months of initial diagnosis or within nine to
12 months of surgery.92,93

Androgen Deprivation Therapy (ADT)
ADT was defined from Medicare outpatient and carrier claims (ICD-9 diagnosis and
procedures codes, HCPCS codes, revenue center codes91) for orchiectomy and gonadotropin-
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releasing hormone (GnRH) agonist received in combination with radiation therapy (within 12
months of initial diagnosis or within nine to 12 months of surgery).

2.3.5 Outcomes
Treatment Completion
Treatment completion was broadly defined based on National Comprehensive Cancer
Network (NCCN) guidelines for breast and prostate cancer, respectively.94,95 For stage I or II
breast cancer, definitive surgical therapy was defined as receipt of BCS or mastectomy within six
months of initial diagnosis, and receipt of radiation after surgery within nine months of initial
diagnosis.96 For stage I or II breast cancer patients who received chemotherapy, completion of
adjuvant chemotherapy was defined as five consecutive months with at least one chemotherapy
claim.97,98 For Stage III breast cancer, treatment completion was defined as BCS or mastectomy,
with radiation therapy following surgery, and adjuvant chemotherapy or hormone therapy (same
guidelines as above). In breast cancer patients with HER2 positive receptor status, receipt of
trastuzumab (Herceptin) and pertuzumab (Perjeta) was required for treatment to be defined as
complete.94 For stage IV breast cancer patients, treatment completion was defined as receipt of
five consecutive months with at least one chemotherapy claim. For stage 0 breast cancer patients
with ductal carcinoma in situ (DCIS), treatment completion was defined as receipt of BCS or
mastectomy within six months of initial diagnosis. Breast cancer patients with stage 0 lobular
carcinoma in situ (LCIS) and patients with unknown stage were excluded from analysis of
treatment completion. For breast cancer patients who received surgery and who were indicated to
receive chemotherapy, time from surgery to chemotherapy was calculated for each study group.
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For prostate cancer, stage I cancer (T1 or T2a), treatment completion was defined as
receipt of a prostate-specific antigen (PSA) blood test or prostate biopsy, radiation therapy, or
prostatectomy within 12 months of initial diagnosis. For stage II cancer (T2b and T2c),
treatment completion was defined as receipt within 12 months of initial diagnosis of radical
prostatectomy with pelvic lymph node dissection or radiation therapy and receipt of ADT. For
stage III cancer (T3), treatment completion was defined as radical prostatectomy and/or receipt
of ADT or receipt of radiation therapy, or radical prostatectomy with receipt of PSA testing or
prostate biopsy. Finally, for stage IV cancer, treatment completion was defined as any
combination of therapy for stage III, with the addition of ADT therapy alone.95

Adverse Events
Adverse events were defined as specific clinical complications requiring hospitalization
known to be associated with hemoglobinopathies including hematuria, renal papillary necrosis,
acute chest syndrome, anemia, ischemia, thrombocytopenia, hyposthenuria, splenic infarction,
rhabdomyolysis, hyphema, venous thromboembolism, priapism, leg ulcers, cholelithiasis, and
stroke.34 We also included other adverse events known to be associated with receipt of
chemotherapy: infections, fever, nausea, leukopenia, diarrhea, dehydration/electrolyte
abnormality, malnutrituion, malaise/fatigue, fractures, headaches, pulmonary conditions,
disorders of lipid metabolism, diabetes, blood transfusion, nephrotoxicity, and cardiac events.99
In addition, we defined adverse events as those putatively related to sickle cell trait and
other hemoglobinopathies based on case report evidence up to 12 months after cancer diagnosis.
Adverse events included emergency room (ER) visits, neutropenic fever, shortness of breath,
severe chest pain, diffuse body aches, hemiplegia, renal toxicity, hepatic toxicity, hemolysis,
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severe back pain, myalgia, generalized joint pain, multiorgan failure, respiratory distress,
hypoxia, dyspnea, mechanical ventilation, pulmonary embolism, vaso-occulsive crisis, and
mucositis.33,34,79
A dichotomous indicator was created for each adverse event, and the total number of
adverse events was calculated for each of the three study groups. A complete list of adverse
event codes is available in Appendix B.

Mortality and Survival Time
Vital status is captured in SEER data and cause of death (COD) was categorized as sitespecific (breast or prostate cancer) or other COD. Survival time was measured from the date of
diagnosis until death or December 31, 2015 (end of follow-up). For site-specific survival,
patients were censored if they were alive at the end of the study period or died of causes other
than breast or prostate cancer, respectively. For competing risks survival, patients were censored
if they were alive at the end of the study period and considered to have died from a competing
cause if the cause of death was not breast or prostate cancer.

2.4 Statistical Analysis
2.4.1 Descriptive analyses
For each cancer site (breast and prostate), demographic and clinical patient characteristics
were categorized (see section 2.3.2) and frequency distributions of categorical variables were
compared in combined analysis using chi-square tests across the three comparison groups:
AA/B+, AA/B-, NHW-. ANOVA (Kruskal Wallis non-parametric method) was performed for
continuous variables across the three study groups.
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2.4.2 Propensity score weighting
As in any observational study, the demographic, clinical, and treatment characteristics
among AA/B+, AA/B-, and NHW- patients could be unequally distributed, resulting in a
selection bias not fully controlled in multivariable ‘adjusted’ analyses. Hence, three-way
propensity score weighting was performed for each cancer site (breast, prostate) to create
similarly situated (i.e. balanced) comparison groups for subsequent estimation of treatment
completion, adverse events, and survival. The generalized boosted model (GBM), a nonparametric machine-learning classifier with multiple iterative regression trees (10,000) was used
to estimate the propensity score for each of the three comparison indicators using the twang
package and mnps() function in R Studio v3.3.2 (R Foundation for Statistical Computing,
Vienna, Austria).100 Separate GBMs were fitted to each comparison group and the probability of
being in the AA/B+ group was estimated, adjusting for the aforementioned demographic and
clinical characteristics, stratified by treatment completion status (i.e. two separate propensity
score analyses performed among those who completed treatment and those who did not complete
treatment; only stratified in estimation of adverse events and survival analysis). Inverse
probability of treatment weighting (IPTW) was used to calculate the ‘average treatment effect’,
or the average effect of having a hemoglobinopathy on a particular outcome.100 Covariate
balance was evaluated graphically (box plots showing the distribution of propensity score by
group), as well as using the standardized population mean differences of <20% (Appendix C).
Any imbalanced covariates still remaining after propensity score weighting were evaluated for
clinical meaning and if differences were determined to be modest, they were included in doubly
robust estimation.100
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2.4.3 Power calculation
Based on the study cohort size of 162,537, with 371 total AA/B+ (nB) patients, the
𝑛

sampling ratio for comparisons with 17,303 AA/B- patients (nA) is represented as, 𝑘1 = 𝑛𝐴 =
𝐵

46.6. The sampling ratio for comparisons with 144,863 NHW- patients (nX) is represented as,
𝑛

𝑘2 = 𝑛𝑋 = 390.5. Assuming a 25% baseline treatment failure rate, 50% baseline adverse event
𝐵

rate, and 5% mortality rate, our study will have sufficient power to analyze a range of effect size
differences in outcomes:
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.930
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2.4.4 Estimation of treatment completion
Receipt of treatment and treatment completion status were compared across study groups
(AA/B+, AA/B-, NHW-) using chi-square tests. Unadjusted and multivariable modified Poisson
regression with robust error variance101 was first performed to estimate the relative risk of
chemotherapy treatment completion across study groups. Adjusted models accounted for
demographic and clinical covariates (see section 2.3.2). Second, Poisson regression with robust
error variance using the propensity weighted study cohort was applied to estimate the association
between hemoglobinopathies and treatment completion.
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2.4.5 Estimation of adverse events
Adverse events (yes vs. no) requiring hospitalization were compared across the three
study groups (AA/B+, AA/B-, NHW-) using chi-square tests. Adverse events were characterized
individually and, in order to account for small sample size, within each of the three groups: 1)
adverse events potentially related to hemoglobinopathies based on case report evidence, 2) other
adverse events potentially related to hemoglobinopathies, and 3) Other adverse events requiring
hospitalization. Unadjusted and multivariable modified Poisson regression with robust error
variance was first performed to estimate the relative risk of being hospitalized for any adverse
event across the study groups. Adjusted models accounted for demographic and clinical
covariates (see section 2.3.2). Second, modified Poisson regression with robust error variance
using the propensity weighted study cohort was applied to estimate the association between
hemoglobinopathies and adverse events, stratified by treatment completion status.

2.4.6 Survival analysis
The propensity score weighted study cohort was used to generate Kaplan-Meier curves
for overall, site-specific, and competing risk survival. Cox proportional hazard regression using
the propensity score weighted study cohort was applied to estimate the association between study
group and overall-, cancer-specific, and competing risks survival. Patients were required to live
up to six months after initial diagnosis to allow patients to survive long enough to initiate and/or
complete treatment. Effect modification of the association between treatment completion and
mortality by the occurrence of one or more adverse event and by study group was tested to
investigate the potentially divergent mechanisms across study groups through which treatment
completion and adverse events were associated with survival.
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All statistical tests were two-sided with a significance level of α = 0.05. As mentioned in
section 2.4.2, propensity score weighting was performed in R Studio v3.3.2 (R Foundation for
Statistical Computing, Vienna, Austria). All other analyses were performed using SAS 9.4 (SAS
Institute, Inc., Cary, NC).

3.0 Results
3.1 Study Cohort
3.1.1 Patient characteristics
Of the 162,537 patients included in the analytic sample (Table 3.1), 75,633 (46.53%)
were breast cancer patients and 86,904 (53.47%) were prostate cancer patients. Median age was
72 (IQR: 69 to 78) for AA/B+, 72 (IQR: 69 to 78) for AA/B-, and 74 (IQR: 69 to 79) for NHW-.
A larger proportion of AA/B+ and AA/B- resided in metro areas (88.68% and 87.75%,
respectively) compared to NHW- (81.43), omnibus p <.001. AA/B+ and AA/B- were more likely
to be diagnosed with stage IV disease (9.97% and 8.71%, respectively) compared to NHWpatients (6.46%, omnibus p <.001). Among breast cancer patients, AA/B+ and AA/B- women
were more likely to have tumors ≥4 cm, more likely to have poorly differentiated (grade 3)
tumors, and more likely to have estrogen and progesterone receptor negative tumors compared to
NHW- women (omnibus p <.001). Among prostate cancer patients, less than 1% of all patients
(n = 845) had Gleason scores from 2 to 4; 56.09% (n=48,744) had scores from 5 to 7; and,
36.81% (n=31,990) had Gleason scores from 8 to 10. Significant differences across the three
study groups were observed for all variables included in Table 3.1.
When analysis of variables listed in Table 3.1 was restricted to a comparison between
AA/B+ and AA/B- patients, only two significant differences (data not shown) emerged: SEER
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Registry Area (p =.008) in that AA/B+ were more likely to reside in the Midwest and less likely
to reside in the South compared to AA/B-); and, the Charlson Comorbidity Index (CCI) score
(36.66% of AA/B+ had a CCI score ≥3 compared to 22.97% for AA/B-; p <.001).
We estimated the prevalence of specific hemoglobinopathies in the analytic study cohort,
prior to excluding NHW+ patients (n = 995). As seen in Appendix D, the proportion of patients
with any hemoglobinopathy was 2.10% (n = 371 of 17,674) for AA/B patients and 0.68% (n =
995 of 145,858) for NHW patients. Overall, the prevalence of every hemoglobinopathy
disorder/variant was more common among AA/B patients compared to NHW patients. Among
AA/B patients, SCT was the most prevalent hemoglobinopathy. The prevalence of SCT was
0.78% (n = 137 of 17,674) for AA/B patients and 0.03% (n = 40 of 145,858) for NHW patients.
These estimates varied somewhat by cancer type for AA/B patients; the prevalence of SCT was
1.11% (n = 77 of 6,919) among AA/B breast cancer patients compared to 0.56% (n = 60 of
10,755) among AA/B prostate cancer patients. The most prevalent hemoglobinopathy among
NHW patients was “other hemoglobinopathies” comprising hemoglobin C and hemoglobin E
disease.
To ensure that the prevalence estimates of hemoglobinopathies in our analytic study
cohort were not subject to selection bias, we estimated the prevalence of hemoglobinopathies in
the SEER-Medicare database prior to having applied exclusions to create the analytic study
cohort (e.g., requirement to be age 66 or older in order to have co-morbidity data in the
preceding year and continuous fee-for-service coverage from one year prior through one year
after cancer diagnosis), and found no appreciable difference in prevalence estimates (<0.1%
difference) (data not shown).
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The distribution of the CCI score by study group is depicted in Figure 3.1. We found that
AA/B+ patients had significantly higher mean CCI scores (2.30, 95% CI: 2.08 to 2.52) compared
to AA/B- patients (1.54, 95% CI: 1.51 to 1.56) and NHW- patients (1.01, 95% CI: 1.00 to 1.02),
respectively (omnibus p <.001). A larger proportion of AA/B- (37.38%) and NHW- (41.01%)
patients had no comorbidities diagnosed in the 12 months prior to cancer diagnosis compared to
AA/B+ patients (22.91%), while a larger proportion of AA/B+ patients had a CCI score of five
or more (16.44%) compared to AA/B- (7.67%) and NHW- (5.93%) patients (Figure 3.1).
Regarding specific comorbidities (Table 3.2), statistically significant (all p <.05)
differences were observed by study group among each of the selected comorbidities (e.g.,
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular
disease, chronic obstructive pulmonary disease, dementia, paralysis, diabetes, diabetes with
sequelae, chronic renal failure, moderate to severe liver disease, ulcers, connective tissue
disorders, AIDS). When analysis was restricted to comparisons between AA/B+ vs. AA/Bpatients (Table 3.2), we found that AA/B+ patients were more likely than AA/B- to have a
history in the 12 months prior to diagnosis of myocardial infarction (2.96% vs. 1.46%),
congestive heart failure (20.75% vs. 12.60%), cerebrovascular disease (18.06 vs. 13.73%),
chronic obstructive pulmonary disease (COPD) (23.72% vs. 17.91%), diabetes (55.53% vs.
38.81%), diabetes with sequelae (22.10% vs. 12.81%), chronic renal failure (25.34% vs.
14.08%), ulcers (3.50% vs. 1.78%), and connective tissue disorders (6.20% vs. 3.24%).

3.1.2 Treatment receipt
Receipt of treatment was stratified by tumor site. For breast cancer patients (Table 3.3), a
total of 65,162 (86.16%) of patients received surgery. Rates of breast-conserving surgery (BCS)
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were lower among AA/B+ (47.59%) and AA/B- (45.81%) patients compared to NHW- patients
(57.3%) (omnibus p <.001), but there were no statistically significant differences between
AA/B+ and AA/B- patients in receipt of surgery or the type of breast surgery, regardless of
AJCC stage or CCI Score. A similar pattern was observed for radiation therapy, in that both
AA/B+ and AA/B- were less likely to receive radiation therapy compared to NHW- (44.39% for
AA/B+, 41.25% for AA/B-, 50.12% for NHW-, omnibus p <.001), yet no statistically significant
difference was observed between AA/B+ and AA/B-. The rate of receipt of any chemotherapy
was slightly higher among AA/B+ (31.02%) and AA/B- (29.96%) breast cancer patients
compared to NHW- (25.87%) patients (omnibus p <.001), but again, no significant differences
emerged between AA/B+ and AA/B- patients. Less than 5.0% of patients within each study
group received neoadjuvant chemotherapy.
Among prostate cancer patients (Table 3.4), a total of 61,760 (71.07%) patients received
initial curative therapy, defined as receipt of prostatectomy, radiation, ADT, or chemotherapy
within 180 days of diagnosis. AA/B- were less likely than NHW- to receive initial curative
therapy (67.51% vs. 71.56%, respectively, p <.001), but rates for AA/B+ (70.11%) did not differ
significantly from the other two study groups. A total of 16,561 (19.06%) of patients received
prostatectomy (including laparoscopic radical prostatectomy with robotic assistance). Rates of
surgery were significantly higher in AA/B- (13.59%) and AA/B+ (12.21%) compared to NHW(20.02%) (p <.001), but there was no statistically significant difference between AA/B+ and
AA/B- patients. No significant differences in receipt of radiation therapy were observed between
the study groups (p =.53). Overall, 29,699 (34.17%) prostate cancer patients received ADT
within 12 months of diagnosis; AA/B- were slightly more likely to receive ADT compared to
NHW- (35.99% vs. 33.91%, respectively, p <.001), but AA/B+ patients (39.67%) did not differ
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significantly in receipt of ADT compared to the other two study groups. Finally, the rate of
receipt of chemotherapy within 12 months of diagnosis was significantly higher among AA/B+
(42.93%) and AA/B- (37.14%) compared to NHW- (35.32%) (p =.03 and p <.001, respectively),
but again, no significant differences emerged between AA/B+ and AA/B- patients (p =.10).

3.2 Treatment Completion
Of the 75,633 breast cancer patients included in the study cohort, a total of 71,078
(93.98%) patients had sufficient data on stage at diagnosis to determine whether treatment was
completed based on NCCN guideline criteria. For prostate cancer, a total of 81,325 (93.58%)
patients had sufficient data on stage at diagnosis to determine whether treatment was completed
based on NCCN guideline criteria. Therefore, a total of 152,403 patients were evaluated for
treatment completion by stage.
Among breast cancer patients, AA/B+ and AA/B- patients had lower rates of treatment
completion compared to NHW- (44.38% vs. 45.40% vs. 52.84%, respectively, omnibus p <.001)
(Table 3.5). This pattern remained consistent when treatment completion was stratified by stage.
Stage II breast cancer AA/B+ patients were marginally less likely than AA/B- stage II breast
cancer patients to complete treatment (22.92% vs 34.81%, p = .08). Cell sizes <11 for AA/B+
with stage III and stage IV breast cancer prevented comparison with AA/B- and NHW- patients.
Among prostate cancer patients, AA/B+ and AA/B- patients had slightly lower overall
rates of treatment completion compared to NHW- (75.74% vs. 74.90% vs. 77.46%, respectively,
omnibus p <.001), driven by the high completion rates in patients with stage I (T1 and T2a)
disease (Table 3.6). For stage II cancer, AA/B+ and AA/B- patients were less likely to complete
treatment compared to NHW- (37.04% vs. 33.47% vs. 43.52%, respectively, omnibus p <.001).
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Cell sizes <11 for AA/B+ with stage III and stage IV breast cancer prevented comparison with
AA/B- and NHW- patients, but AA/B- experienced dramatically lower rates of treatment
completion compared to NHW- patients (stage III AA/B-: 43.37% vs. NHW-: 64.75%, p <.001;
stage IV AA/B-: 59.40% vs. NHW-: 71.92%, p <.001).
Table 3.7 displays the unadjusted and adjusted (both multivariable adjusted and
propensity score weighted) relative risk of incomplete treatment by study group for all patients
and stratified by tumor site. In unadjusted analysis, AA/B+ and AA/B- breast cancer patients had
significantly higher risk of incomplete treatment compared to NHW- patients; this effect
remained significant among AA/B- patients in multivariable adjusted analysis (RR: 1.05, 95%
CI: 1.043 – 1.08, p <.001), but was attenuated and did not remain significant in propensity score
weighted analysis (RR: 1.01, 95% CI: 0.96 – 1.05, p = .82). Pairwise comparisons between
AA/B+ and AA/B- patients revealed no significant differences in adjusted risk of treatment
completion, overall or by tumor site (data not shown).
AA/B- prostate cancer patients were significantly less likely to complete treatment
compared to NHW- patients in unadjusted, multivariable adjusted, and propensity score
weighted analysis (propensity score weighted RR: 1.17, 95% CI: 1.12 – 1.22, p <.001), but no
statistically significant differences in risk of incomplete treatment were observed between
AA/B+ vs. NHW- patients (Table 3.7). Pairwise comparisons between AA/B+ and AA/Bpatients revealed no significant differences in adjusted risk of treatment completion, overall or by
tumor site (data not shown). Details and diagnostic assessment of the propensity score weighted
analysis are presented in Appendix C.
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3.3 Adverse Events
Patients who received treatment were evaluated for the incidence of adverse events
requiring hospitalization during follow-up (Table 3.8). A total of 69,531 (91.9%) breast cancer
patients and 65,505 (75.4%) prostate cancer patients received treatment after cancer diagnosis,
defined as receipt of any surgeryviii, radiation, chemotherapy, hormone therapy, or ADT. Over
half of the breast cancer patients who received no treatment were diagnosed as stage IV or with
unknown stage, and approximately 60% of the prostate cancer patients were received no
treatment were diagnosed as stage I (T1 or T2a), where watchful waiting or active surveillance
(PSA test and/or prostate biopsy) is recommended, particularly for older patients with expected
survival <20 years.95
Overall, 89,479 treated patients (66.26%) experienced at least one adverse event
requiring hospitalization; nearly half of all treated patients had an emergency room visit (n =
64,165; 47.52%). Of the 81,797 patients who received surgery, 9,969 (12.19%) experienced an
adverse event within 90 days; AA/B+ (15.64%) and AA/B- (14.37%) patients were more likely
to experience an adverse event following surgery compared to NHW- (11.99%) patients
(omnibus p <.001), but there was no significant difference between AA/B+ and AA/B- patients
(p= .63). A similar trend was observed for adverse events occurring within 6 months following
receipt of chemotherapy or ADT (Table 3.8). When adverse events were categorized into three
groups (known associations with hemoglobinopathies, putative associations with
hemoglobinopathies, known toxicity associated with cancer therapy) (Table 3.8, Figure 3.2), we
observed that AA/B+ had a significantly higher proportion of adverse events in all three
categories compared to both AA/B- and NHW- patients (each p <.001). In addition, AA/B+

viii

Breast cancer: receipt of BCS or mastectomy within 6 months of diagnosis; Prostate cancer: receipt of
prostatectomy within 12 months of diagnosis.
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patients had a significantly higher proportion of emergency room visits compared to NHWpatients, and a marginally significantly higher proportion of emergency room visits compared to
AA/B- patients (p =.065).
Among all treated patients, AA/B+ had increased propensity score weighted risk of
experiencing one or more adverse event compared to both AA/B- (RR: 1.15, 95% CI: 1.07 –
1.24, p <.001) and NHW- (RR: 1.18, 95% CI: 1.10 – 1.26, p <.001) (Table 3.9). The magnitude
and significance of this relationship was similar for breast and prostate cancer patients (Table
3.9).
Among breast cancer patients who completed treatment (Table 3.10), the risk of
experiencing one or more adverse event requiring hospitalization or an emergency room visit
was 1.18 times higher for AA/B+ patients vs. NHW- (multivariable adjusted 95% CI: 1.06 –
1.32, p =.002; propensity score weighted 95% CI: 0.98 – 1.42; p=.084). Likewise, AA/B+
patients also were 1.17 times more likely than AA/B- to have experienced an adverse event
requiring hospitalization or ER visit (multivariable adjusted 95% CI: 1.05 – 1.31, p =.004;
propensity score weighted 95% CI: 0.97 – 1.41, p=.098). In contrast, no significant differences in
risk of hospitalization were observed between AA/B- and NHW- patients.
For prostate cancer patients who completed treatment (Table 3.10), a statistically
increased risk of an adverse event requiring hospitalization or ER visit was observed in all
analyses for AA/B+ patients compared to NHW- and AA/B- patients. Specifically, the
propensity score weighted risk of experiencing one or more adverse events was 1.22 times
greater for AA/B+ vs. NHW- (95% CI: 1.09 – 1.36, p <.001). The propensity score weighted risk
of experiencing one or more adverse events was 1.17 times greater for AA/B+ vs. AA/B- (95%
CI: 1.06 – 1.31, p =.003) for prostate cancer patients who completed treatment. AA/B- patients
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were at small but significantly increased risk for adverse events compared to NHW, in both
propensity score weighted (RR: 1.04, 95% CI: 1.01 – 1.07, p =.020) and multivariable adjusted
(RR: 1.05, 95% CI: 1.03 – 1.07, p <.001) analysis.
Among breast cancer patients who did not complete treatment (Table 3.11), AA/B+
patients had increased propensity score weighted risk of adverse events compared to both NHW(RR: 1.14, 95% CI: 1.01 – 1.26, p =.018) and AA/B- (RR: 1.13, 95% CI: 1.02 – 1.25, p =.024)
patients. No statistically significant differences were observed between AA/B- and NHWpatients in adjusted analysis.
Among prostate cancer patients who did not complete treatment (Table 3.11), AA/B+
patients had increased multivariable adjusted risk of adverse events compared to both NHW(RR: 1.18, 95% CI: 1.06 – 1.31, p =.002) and AA/B- (RR: 1.15, 95% CI: 1.03 – 1.28, p =.009),
but these effects did not remain statistically significant in propensity score weighted analysis. No
statistically significant differences were observed between AA/B- and NHW- patients in adjusted
analysis.
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3.4 Survival
3.4.1 Mortality and Kaplan-Meier Survival Curves
Median follow-up time was 53 months (IQR: 33 - 77) and 59 months (IQR: 37 - 82) for
breast and prostate cancer patients, respectively. Of those surviving to the end of the study
period, median follow-up time was significantly different across study groups in both cancer
sites. That is, for surviving breast cancer patients, median follow-up time was 59.5 months (IQR:
45 to 85) for AA/B+, 60 months (IQR: 40 to 81) for AA/B-, and 62 months (IQR: 42 to 83) for
NHW-. For corresponding prostate cancer patients, median follow-up time was 68 months (IQR:
47 to 88) for AA/B+, 65 months (IQR: 46 to 86) for AA/B-, and 67 months (IQR: 47 to 88) for
NHW-. It is unlikely that differences in follow-up time among surviving patients across study
groups represent clinically meaningful difference in the adequacy of the follow-up time.
Regarding mortality among breast cancer patients, 57 AA/B+ (30.48%), 6,732 AA/B(36.41%), and 19,230 NHW- (27.99%) patients died during the study period (omnibus p <.001)
(Table 3.12). AA/B- were more likely to die from both breast cancer and competing causes
compared to NHW (p <.001), but no significant differences were observed between AA/B+ and
NHW- or between AA/B+ and AA/B-. Overall, 2-year and 5-year survival differed only between
AA/B- and NHW- patients (Table 3.12).
Among prostate cancer patients (Table 3.12), a total of 75 AA/B+ (40.76%), 3,310
AA/B- (31.31%), and 19,507 NHW- (25.62%) patients died during the study period (omnibus p
<.001). Furthermore, pairwise comparisons revealed that the rate of AA/B+ mortality was higher
than both AA/B- (p =.006) and NHW- (p <.001) groups. Regarding cause-specific death,
proportionately more AA/B+ patients died from prostate cancer (n = 17, 9.24%) compared to
NHW (n = 4,201, 5.52%, p =.004) and AA/B- patients (n= 783, 6.98%), but the AA/B+ vs.
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AA/B- difference did not reach statistical significance (p =.10). Similarly, proportionately more
AA/B+ patients died from other causes (n = 58, 31.52%) compared to NHW (n = 15,306,
20.10%), p <.001) and AA/B- patients (n= 2,572, 24.33%, p =.013).
Two-year and 5-year survival rates (Table 3.12) were significantly higher (all p <.001)
among NHW- prostate cancer patients (2-year: 92.74%, 5-year: 79.90%) compared to both
AA/B- (2-year: 90.06%; 5-year: 74.59%, respectively) and AA/B+ patients (2-year: 87.43%, 5year: 67.95%, respectively). In contrast, no statistically significant differences were observed
between AA/B+ and AA/B- patients. Unadjusted and propensity score weighted Kaplan-Meier
curves illustrating the aforementioned 2-year and 5-year survival patterns per outcome (i.e., allcause, cancer-specific, and non-cancer deaths) are presented for breast cancer (Figure 3.3) and
prostate cancer (Figure 3.4).

3.4.2

Cox Proportional Hazards Survival Analyses
The propensity scores generated for use in Cox proportional hazards models included

demographic characteristics (age, year of diagnosis, marital status, SEER region, income, and
education) as well as stage, CCI score, and number of positive lymph nodes. For breast cancer
patients, additional covariates were tumor grade, tumor size, histology, estrogen receptor status,
progesterone receptor status, and HER2 receptor status. For prostate cancer patients, the
propensity score model included Gleason score.
While the propensity score weighted hazards models failed to reveal significant
differences in mortality risk across study groups, the magnitude of the associations with
mortality in relation to either treatment completion (no vs. yes) or adverse events (≥1 vs 0)
significantly varied by hemoglobinopathy status Specifically, as depicted in Figure 3.5, the risk
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of mortality among AA/B+ patients was 1.29 (95% CI: 1.23 – 1.36, p <.001) times greater
among those who failed to complete treatment compared to those who completed treatment, yet
the relative difference in mortality was greater in both AA/B- and NHW- groups (HR: 2.05, 95%
CI: 1.96 – 2.15, p <.001); HR: 2.32, 95% CI: 2.22 – 2.43, p <.001; respectively).
Regarding adverse events and mortality (Figure 3.6), the risk of mortality among AA/B+
patients was 4.78 (95% CI: 4.23 – 5.41, p <.001) times greater among patients experiencing one
or more adverse event compared to those who did not experience an adverse event. Unlike the
trend for treatment completion analyses, however, the adverse event-mortality effect was
attenuated significantly among both AA/B- (HR: 3.28, 95% CI: 3.06 – 3.51, p <.001) and NHWpatients (HR: 3.16, 95% CI: 2.96 – 3.37, p <.001). Compared to NHW-, AA/B+ had a 1.13 (95%
CI: 1.08 – 1.18) times higher risk of mortality if they completed treatment and experienced 1 or
more adverse event. Compared to AA/B-, AA/B+ had a 1.11 (95% CI: 1.06 – 1.16) times higher
risk of mortality if they completed treatment and experienced 1 or more adverse event.
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4.0 Discussion
4.1 Summary of Key Findings
In this retrospective cohort study of patients diagnosed with breast (female) and prostate
cancer from 2007 to 2013 in the SEER-Medicare linked database, we found that AA/B patients
diagnosed with hemoglobinopathies experienced higher rates of adverse outcomes compared to
similarly situated AA/B and NHW cancer patients not diagnosed with hemoglobinopathies.
Specifically, we found that compared to AA/B- and NHW- patients, AA/B+ patients experienced
increased risk of one or more adverse event requiring hospitalization following treatment
initiation, and the risk of mortality was significantly higher among AA/B+ patients who
experienced one or more adverse event compared to AA/B- and NHW- patients who experienced
one or more adverse event.
We observed significant differences across patient, clinical, and tumor characteristics by
study group, but apart from SEER region and CCI score, these differences were driven by race;
AA/Bs, regardless of hemoglobinopathy status, were more likely to be diagnosed with cancer at
younger ages (66 – 74), reside in a metro area, have a lower median household income, not
married, and diagnosed with stage IV disease. Among breast cancer patients, AA/Bs had larger
tumors ≥4 cms (breast cancer), poorly differentiated grade tumors (breast cancer), and had higher
proportions of estrogen and progesterone receptor status negative cancers.
The observed differences between AA/B+ and AA/B- revealed that AA/B+ patients were
more likely to reside in the Midwest and less likely to reside in the South compared to AA/Bpatients. In addition, AA/B+ patients had a significantly lower proportion of CCI scores of 0, and
significantly higher proportion of scores of 4 and 5 or more, compared to NHW- and AA/B-.
When differences in individual comorbidities were compared across study groups, myocardial
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infarction, congestive heart failure, diabetes, diabetes with sequelae, chronic renal failure, and
ulcers were significantly more common not only among AA/B+ compared to NHW-, but among
AA/B+ compared to AA/B- as well. When differences across comorbidities were further divided
across specific hemoglobinopathy groups (SCT, SCD, thalassemia, other), we found that SCT
was primarily responsible for the observed group differences. Finally, NHW patients who
appeared in the dataset as having a hemoglobinopathy (NHW+) did not follow the same trend
(Appendix D).
While no statistically significant differences were found in the adjusted risk of treatment
completion between AA/B+ cancer patients compared to NHW- or AA/B- patients, respectively,
we found that AA/B- prostate cancer patients had an estimated 17% increased risk (95% CI: 12%
to 22%, p <.001) of incomplete treatment compared to NHW- patients. It is possible that the
AA/B+ study group lacked the statistical power needed to detect a true effect if it existed.
Irrespective of power considerations, no statistically nor clinically meaningful differences
emerged between AA/B+ vs. AA/B- in regards to treatment completion, which could reflect
actual clinical practice, or could be an artifact of how treatment completion was defined in our
analysis.
The overall proportion of adverse events requiring an emergency room visit or
hospitalization experienced among patients who initiated treatment was significantly higher
among AA/B+ compared to both NHW- and AA/B-. Approximately 28% of all AA/B+ patients
experienced 3 or more adverse events, compared to only 15% and 13% in AA/B- and NHW-,
respectively. In addition, AA/B+ patients were significantly more likely to experience adverse
events known or putatively known to be associated with hemoglobinopathies as well as other
chemotherapy-related adverse events. The adjusted risk of experiencing one or more adverse
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event was approximately 14% higher for AA/B+ compared to both AA/B- and NHW- breast
cancer patients who failed to complete treatment; while this effect was not significant among
prostate cancer patients who failed to complete treatment, a 17% and 22% increased risk of one
or more adverse event was observed for AA/B+ prostate cancer patients who did complete
treatment compared to AA/B- and NHW- patients, respectively. The relative risk of adverse
events was marginally increased among AA/B+ compared to AA/B- and NHW- breast cancer
patients who completed treatment (17% and 18%, respectively). When the requirement for
having initiated treatment was removed and adverse events were explored in the entire study
population (n = 162,537), AA/B+ had 17% increased risk of experiencing one or more adverse
event compared to NHW- (95% CI: 10% to 26%, p <.001) and a 15% increased risk compared to
AA/B- (95% CI: 8% to 24%, p <.001). This effect remained consistent when adverse events were
isolated to inpatient hospitalizations, suggesting that AA/B+ cancer patients are not only more
likely to experience a larger proportion of adverse events, but also more severe adverse events
compared to AA/B- and NHW- patients across the entire spectrum of cancer care.
To test the underlying assumption that adverse events were treatment-related and not just
due to existing comorbidities or an unobserved confounding factor, we examined the risk of
adverse events, stratified by CCI score (Figure 4.1). Among patients with no comorbidities,
AA/B+ patients experienced 35% increased risk of experiencing one or more adverse event
compared to NHW- (95% CI: 15% to 60%). This trend was attenuated (e.g., 18% (95% CI; 6%
to 30%) for CCI=1; 26% (95% CI: 16% to 38%) for CCI=2; 6% (1% to 28%) for CCI=3; 4%
(1% to 14% for CCI=4), but remained significant across CCI Scores, and was proportionately
higher than the association between AA/B- compared to NHW- across CCI Scores from 0 to 2.
(Figure 4.1).
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In propensity score weighted survival analysis, no apparent overall survival differences
emerged between AA/Bs (independent of hemoglobinopathy status) and NHW-. When we
explored potential factors through which each study group experienced mortality, however,
treatment completion and adverse events were identified as significant effect modifiers.
Specifically, while patients in all three study groups who experienced at least one adverse event
were far more likely to die compared to those with no reported events, the relative difference in
mortality was highest within the AA/B+ patient group. In contrast, when comparing mortality
risk among AA/B+ patients who did not complete treatment versus those who did, the relative
difference was the lowest among the three study groups. A coherent explanation for these
divergent patterns of effect modifications might be that while AA/B+ patients might be just as
likely to fail to complete treatment as AA/B- and NHW- patients, the specific reasons for
discontinuation among AA/B+ patients confer a greater risk of mortality. By extension, we posit
that the higher risk of AA/B+ patients to experience one or more adverse events suggests that
these events are comparatively deadlier to AA/B+ compared to AA/B- and NHW- patients. Our
findings suggest, therefore, that occurrence of an adverse event poses a more serious threat to
mortality than does not completing treatment.
This interpretation also is supported by the variation in the magnitude of the interaction
between treatment completion and adverse events across the study groups (Figure 4.2). Among
AA/B+ patients who completed treatment, those who experienced one or more adverse events
had more than five times the risk of dying than those for whom there were no reports of adverse
events whereas the estimated relative risks of mortality among AA/B- and NHW- patients were
about three-fold. Among patients who failed to complete treatment, however, the relative risks of
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mortality for patients experiencing one or more adverse events was similar across groups (HRs
of 2.64 to 3.28 with overlapping 95% CIs.

4.2 Consistency with Existing Evidence and Biologic Plausibility
This research presents the first observational, population-based study investigating the
association between inherited hemoglobinopathies and cancer outcomes, and as such there is
limited existing evidence to compare for consistency. On a broad scale, studies investigating
racial disparities in cancer outcomes can be used as a benchmark to compare the magnitude of
treatment completion, adverse events, and survival outcomes. Our results can also be put into
context with other observational studies measuring the impact of SCT and other
hemoglobinopathies on a variety of chronic conditions and diseases including chronic kidney
disease38, stroke39, and pulmonary embolism40. Existing evidence for the association between
hemoglobinopathies and cancer outcomes is limited to a collection of case reports published by
Swede et al. in 201411 and the preliminary chart review conducted using the CTR (See Section
1.2). Our results are consistent with case report evidence among patients with SCT, SCD, and
other combinations of hemoglobin variants who were diagnosed with cancer and receiving
therapy, which revealed instances of painful crises and other adverse effects requiring
hospitalization including neutropenia, pulmonary embolism, renal toxicity, respiratory distress,
and multi-organ failure. Our results are also consistent with findings from a preliminary chart
review in breast cancer patients undergoing treatment which suggested that women with SCT
experienced a higher proportion of total adverse events compared to women without SCT.
The biologic mechanisms underlying the association between hemoglobinopathies and
cancer-related adverse events are not well defined, but we propose that cancer patients with
inherited hemoglobinopathies, particularly SCT, are at increased risk for adverse events when
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exposed to physiologic stressors. Stressors in the form of existing tumor hypoxia, surgery,
radiotherapy, or systemic chemotherapeutic agents may lead to RBC sickling, vaso-occulsive
crises, and a host of additional complications. Evidence from case reports and in vivo animal
studies suggest that intravascular sickling within the tumor microenvironment may be promoted
by acidosis and results in increased hypoxia. Sickle cells are considered in the literature as a sitespecific contrast agent due to their propensity to preferentially accumulate in the tumor
vasculature through impaired blood flow and oxygenation, but this may ultimately result in
vascular hemolysis, vaso-occulsion, and further hypoxia and organ damage.102 Via upregulation
of HIF-1, hypoxia induces expression of genes that drive tumor growth (by promoting
angiogenesis), proliferation, and metastatic potential.103 Pretreatment tumor hypoxia is a known
prognostic factor for survival after treatment with radiation alone or in combination with surgery
or chemotherapy, and combined treatments are demonstrably less effective in hypoxic tumors.104
From a mechanistic perspective, hypoxia confers treatment resistance by inhibiting apoptosis and
producing quiescent, stem-cell like cell fractions least affected by anticancer treatments targeting
rapidly proliferating cells. In addition to disrupting the cellular environment, the hypoxic
microenvironment facilitates tumor growth via angiogenesis, leading to suppression of antitumor immune cells and escape from immune surveillance.103 Multiple studies have found
sickled RBCs target the hypoxic tumor vascular microenvironment and subsequently include
vaso-occlusion, autohemolysis leading to endothelial injury.60,61 In a small study comparing 10
SCD vs. 10 wild-type mice, the tumor growth rate was accelerated in SCD mice compared to
wild-type, enhanced by HO-1 activity and angiogenesis.60
In addition to tumor hypoxia, we propose the associations between hemoglobinopathies
and other conditions including chronic kidney disease, diabetes, and pulmonary embolism play a
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role in the occurrence of adverse events requiring hospitalization among cancer patients. While
our results suggested that AA/B+ have increased risk of adverse events compared to NHW-and
AA/B- across CCI scores, there is evidence to suggest that the specific type of comorbidity may
impact outcomes. For example, the prevalence of comorbid diabetes in our study was
significantly higher among AA/B+ (55.5%) compared to AA/B- (38.8%) and NHW- (24.3%). In
the epidemiological literature, diabetes has been found to be associated with significantly higher
all-cause mortality across all types of cancer, and higher cancer-specific mortality in patients
diagnosed with cancer of the breast, endometrium, and colorectum.105,106 The association
between diabetes and cancer mortality persists even after adjustment for age, BMI, physical
activity, and other dietary factors.107 From a biological perspective, the association between
diabetes and cancer mortality could be explained indirectly via the shorter overall life expectancy
among individuals with diabetes.108 More direct associations include hyperglycemia, and to a
lesser extent, impaired immune function and/or pro-inflammatory conditions, known to be
associated with tumor cell proliferation and survival.107,109
In addition to diabetes, recent observational studies have documented independent
associations between SCT and chronic kidney disease38, stroke39, ESRD37, and pulmonary
embolism40. Among patients with no comorbidities in our study, we found that the risk of
experiencing a pulmonary embolism or venous thromboembolism was significantly higher
among AA/B+ compared to both AA/B- and NHW-, but did not find any significant increase in
the risk of renal failure or stroke in AA/B+ compared to AA/B- or NHW-. We did find, however,
that AA/B+ had an increased risk of heart failure and other cardiovascular complications, as well
as anemia, pain, respiratory dysfunction, and emergency room visits compared to AA/B- and
NHW- (Appendix D). A recent meta-analysis of 4 different US population-based cohorts
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concluded that the presence of SCT was not associated with an increased risk of heart failure or
alterations in cardiac structure or function110, so further investigation may be warranted to better
understand the relationship between hemoglobinopathies and cardiovascular-related events in the
context of cancer. For thromboembolism, the coagulation pathway is activated by elevated levels
of d-dimers and monocytes in SCT carriers, which in turn poses an increased risk of vasoocclusive crises among patients with sickle cell disease.111 Dirix et al. (2002) found that plasma
levels of d-dimers are associated with cell proliferation and tumor growth, metastatic potential,
and shorter overall survival in breast cancer patients. Our results provide indirect evidence to
support the association between hemoglobinopathies and thromboembolism in the setting of
cancer, and suggest that the development of thrombosis may reflect the presence of a
biologically more aggressive cancer that in turn leads to a worse prognosis. Further exploration
into the potential pathways through which SCT and thromboembolism interact to impact cancer
outcomes may be important for understanding the overall burden of thrombosis in cancer, given
that cancer patients account for 20% of all patients with venous thromboembolism and
thrombosis is believed to account for 9% of all cancer-related deaths.112

4.3 Strengths and Limitations
The utilization of SEER-Medicare database is the greatest strength of this study, as it is a
population-based cancer database that contains information on hemoglobinopathy diagnosis from
medical claims. Data from SEER has the benefit of very low loss to follow-up and contains
detailed tumor characteristics and cause of death. The Medicare database provides a near 100%
linkage to individuals appearing in the SEER program, which increases the external validity of
the study in regards to generalizability of the results to the US elderly population.
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The primary limitation regarding the use of administrative claims to identify
hemoglobinopathies is the potential for misclassification bias; in the general population, many
individuals with hemoglobinopathy variants, particularly SCT, are unaware of their status. This
is reflected in the low prevalence of SCT and other hemoglobinopathies in our study cohort,
particularly for AA/B (1.74% for hemoglobinopathies; 0.63% for SCT), where the population
prevalence is estimated to be approximately 8% and has been confirmed in other observational
studies investigating the association between SCT and health outcomes.38 Further, it is likely
that a proportion of patients in our study were incorrectly classified as not having a
hemoglobinopathy, since diagnosis depended on having a claim for the condition. This
limitation, however, would bias our comparisons between AA/B+ and AA/B- study groups
towards the null.
Another limitation in this observational study is the potential for selection bias and
confounding by unobserved variables such as performance status (e.g. activities of daily living
status, functional status, and patient quality of life) used to summarize ability of a patient to
tolerate aggressive treatment, current smoking status, body mass index, various metabolic
functions, and treatment dose adjustments. For example, it is possible that patients with
hemoglobinopathies and associated conditions (i.e. renal failure) are subject to more dose
adjustments during cancer therapy compared to patients without hemoglobin variants113, which
could bias results either away from or towards the null. Based on our hypothesis that increased
tumor hypoxia is the primary mechanism through which patients with hemoglobinopathies
experience worse clinical outcomes, another important limitation of this study is the absence of
tumor hypoxia assessment. Since our diagnosis data are based on administrative claims, it is
likely that we underestimated comorbidities even though we captured comorbidity claims during
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the 12 months prior to diagnosis. Our study was also limited to individuals ages ≥66 and those
with continuous Medicare Part A and B/non-HMO coverage, potentially limiting the overall
generalizability of results to the entire older adult population, although there is evidence to
suggest comparable diagnosis and treatment characteristics between managed care and fee-forservice plans.114
Finally, this study lacked adequate sample size and power to investigate the association
between hemoglobinopathies and adverse cancer-related outcomes in individuals with genetic
ancestry other than AA/B and NHW, specifically individuals with Southeast Asian and Middle
Eastern ancestry. The increase among immigrant populations in the US from Asian and Arab
countries with high prevalence of hemoglobinopathies suggest our results may be applicable to
other races, but our study did not have sufficient sample size to perform these analyses. Further,
in many studies that deliberately investigate cancer outcomes in racial minorities, Asian
populations are often grouped together, potentially masking certain effects that could be
associated with hemoglobinopathies. A recent SEER study found that South Asian and "other
Asian" (Asian Indian, Pakistani, Filipino, Thai, Vietnamese, Laotian) women exhibit more
aggressive breast cancer, similar to the magnitude experienced by AA/Bs, when compared to
Japanese Asian groups.13

4.4 Future Research Directions
The present study has documented the clinical profile of AA/B+ cancer patients in
comparison to AA/B- and NHW- patients as well as revealed associations between
hemoglobinopathy status and treatment completion, adverse events, and mortality. Given the
nature of observational data analysis, in combination with the relatively limited existing research
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into the association between hemoglobinopathies and adverse cancer outcomes, our results have
generated additional hypotheses for future exploration. The framework for our interpretation was
based on hypothesis-driven results suggesting that AA/B+ status and the occurrence of adverse
events acted to modify the effect of treatment completion on mortality. Specifically, we observed
that AA/B+ patients who completed treatment had proportionately increased risk of death
compared to those who failed to complete treatment. This exaggerated effect was not observed in
AA/B- or NHW- patients. Furthermore, the increased risk of death for AA/B+ who completed
treatment also was increased among patients who experienced one or more adverse event. One
explanation for this result is that AA/B+ patients exposed to extended treatment leading to
completion were subject to more severe physiologic stressors that resulted in a larger proportion
of adverse events. It is likely the case, however, that adverse events also inform whether
treatment is completed. In the latter situation, adverse events act not only to moderate the
association between treatment completion and mortality, but also confound the association
between treatment completion and mortality.
Outside of the current investigation using the SEER-Medicare database, there are
opportunities to conduct similar studies using a variety of analytical techniques in additional
databases. In their investigation into the association between SCT and chronic kidney disease,
Naik et al. (2014) pooled data across five large, prospective, US population-based cohorts
(ARIC, JHS, CARDIA, MESA, WHI)ix, resulting in more than 15,000 AA/B individuals overall
and 1,248 individuals with SCT (prevalence ranged from 6.3% to 9.3% among study cohorts).38
Identification of SCT was ascertained through custom genotyping, exome sequencing, and
imputation. While it is not possible to obtain genotyping data (‘gold standard’) for the SEER-

ix

ARIC: Atherosclerosis Risk in Communities Study; JHS: Jackson Heart Study; CARDIA: Coronary Artery Risk
Development in Young Adults; MESA: Multi-Ethnic Study of Atherosclerosis; WHI: Women’s Health Initiative
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Medicare cohort, we are currently investigating natural-language processing as a tool to abstract
hemoglobinopathy status from clinical notes that would appear in an electronic medical record
(EHR). While clinical notes are not as sensitive as genomic profiling data for determining SCT
or other hemoglobinopathy status, they are more likely to be available in clinical settings for a
larger proportion of the population overall compared to genotype data, and they are more likely
to produce more accurate estimates of hemoglobinopathy prevalence compared to medical
claims. Although universal newborn screening for hemoglobinopathies has only been in effect in
the US since 2006, an increasing proportion of the population are becoming aware of their status.
It will be of great importance for clinical health providers to ethically ascertain
hemoglobinopathy status from patients to ensure this information is available in EMRs.
In addition to having genotype data available for identifying SCT status, Naik et al.
utilized pooled data across research cohorts. Upon receiving approval from both the NCI and
Mayo Clinic, we will have the ability to pool data in a similar manner in order to increase the
overall power of future investigations. In addition to SEER-Medicare and Mayo Clinic
databases, we are also exploring the ability to link to other prospective cohorts or EMRs with
tumor registry data. The WHI was utilized by Naik et al. to analyze the association between SCT
and chronic kidney disease; we have proposed to use the WHI data in a similar manner to assess
cancer outcomes.
The Mayo Clinic database signifies two additional important future directions for
investigating the relationship between hemoglobinopathies and cancer related adverse events.
First, since the Mayo Clinic data comes from a tumor registry linked to an EMR and does not
rely solely on claims for identification of hemoglobinopathies, analysis will not be limited to
patients age ≥65. Second, the Mayo Clinic data contains data on other cancer sites in addition to
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breast and prostate cancer. The SEER-Medicare database has this information available as well,
but each cancer site needs to be requested separately and comes with an additional fee. While
breast and prostate cancer represent excellent exemplar cancer sites due to their high prevalence
in the population and the large outcome disparities observed between AA/B and NHW patients,
there is evidence to suggest other solid tumors may be more sensitive to the adverse effects of
hypoxia (i.e. head and neck cancer, cervical cancer). In addition, outcome disparities by race are
not limited to breast and prostate cancer—disparities are documented across cancer sites
including cancer of the colorectum, stomach, lung and bronchus, ovary, cervix, and uterine
corpus.1

4.5 Translational Implications
Despite overall improvements in cancer-specific mortality rates since the 1990s in all
groups, largely attributed to the introduction of improved cancer therapies and screening, racial
disparities in outcomes persist between AA/B and NHW populations.1 While SCT has been
historically considered a benign condition not associated with decreased life expectancy, a
growing number of clinical complications have been found to be associated with SCT. Our study
adds adverse cancer outcomes to the list of complications associated with SCT and other
inherited hemoglobinopathies known to have a higher prevalence in AA/B populations. At
present, hemoglobinopathies are not established as a clinically relevant prognostic indicator
among patients with cancer, and therefore providers have no reason to obtain information from
patients regarding their status. From a translational perspective, it will be important for providers
to communicate with patients regarding the potential risks and treatment considerations
associated with carrier status. Despite universal newborn screening in the US, survey estimates
suggest that only 16% of the adult population with SCT is aware of their status.115 This fact is
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reflected in the prevalence estimates of hemoglobinopathies in our study cohort. Assuming an
8% prevalence of SCT, only 10% of AA/B patients expected to have SCT had claims and were
therefore likely aware of their status (7% for prostate cancer patients and 13.9% for breast cancer
patients).
In the preliminary CTR chart review, breast cancer patients were informed of their SCT
carrier status after a complication occurred. In the SEER-Medicare study cohort, approximately
60% of patients had a claim for a hemoglobinopathy after diagnosis. Claims are an imperfect
proxy for the timing of when a patient learns about her/his hemoglobinopathy status, but it
suggests and perhaps confirms that a majority of cancer patients are informed of their
hemoglobinopathy status after cancer diagnosis. Based on this information, health care providers
may be responsible for taking initiative to communicate with patients about whether they have a
hemoglobinopathy, and potentially to screen individuals who have immigrated from or have
ancestry from an area with a high prevalence of SCT or thalassemia. Overall, the timing of a
hemoglobinopathy claim did not appear to be associated with treatment completion or vital status
in the SEER-Medicare cohort.
Results from this study prompt a number of translational science research questions.
First, a deeper understanding of the potential histologic differences in the tumor
microenvironment between patients with hemoglobinopathies and those without will elucidate
associations between hypoxia and intratumoral sickling. In a case report documenting
intratumoral sickling in a patient with cervical cancer and sickle cell trait, Milosevic et al. (2001)
obtained a punch biopsy of the tumor which confirmed moderately differentiated invasive
squamous cell carcinoma, with extensive RBC sickling and severe hypoxia.48 The amplification
cycle of tumor hypoxia and RBC sickling leading to enhanced tumor growth and reduced
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sensitivity to radiation and chemotherapy has important clinical implications regarding modified
treatment and monitoring plans. Results from our observational study provide indirect evidence
to suggest that hemoglobinopathies influence the occurrence of adverse events and patient
mortality, but further histologic study of cancers in individuals with SCT is warranted. In
addition to SCT, it is worthwhile to consider additional hemoglobinopathies as well to determine
if a similar mode of action appears across a range of hemoglobinopathies.
Overall, results from this retrospective observational research study represent the first
formal population-based study of SCT and other hemoglobinopathies as an adverse prognostic
factor in older adults with cancer. In his 2015 State of the Union Address, President Barack
Obama announced a new Precision Medicine Initiative, “…to bring us closer to curing diseases
like cancer and diabetes – and to give all of us access to the personalized information we need to
keep ourselves and our families healthier”.116 The concept of precision medicine focuses
specifically on cancer, aiming to gain insight into inherited genetic variations that drive disease
prevention, treatment, prognosis, and outcomes on a population scale.116 The present
investigation of the prognostic influence of inherited hemoglobin variants and their subsequent
contribution to racial disparities in cancer outcomes falls perfectly into the framework of
precision medicine. This framework also provides a roadmap to future studies measuring the
pharmacogenomics for SCT carriers with cancer, allowing treatment dose, intensity, and overall
plan to be tailored for each individual patient, thereby giving this patient population the greatest
chance to reduce morbidity and improve survival outcomes.
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Tables
Table 1.1. CTR Preliminary chart review: Demographic and clinicopathological
characteristics by study group

Characteristics
Median follow-up, months (IQR)
Age at diagnosis, mean (SD)
Stage
0
I
II
III
IV
BMI, mean (SD)
Vital status
Alive
Dead
Smoking history
Never
Former
Current
NOS
Number of comorbid conditions
(CCIa Score)
0
1
2+
missing
Family history of cancer
a

AA/B SCT +
(n = 12)
46 (30 - 115)
55.5 (12.9)

Clinical Phenotype
NHW SCT +
AA/B SCT (n = 2)
(n = 40)
62 (53 - 71)
88 (44 - 138)
46.0 (6.4)
53.5 (9.8)

NHW SCT (n = 40)
99 (60 - 133)
54.6 (11.3)

1 (8.3)
5 (41.7)
3 (25.0)
3 (25.0)
-33.5 (7.1)

1 (50.0)
1 (50.0)
---25.2 (0.0)

4 (10.0)
10 (25.0)
20 (50.0)
6 (15.0)
-32.8 (10.0)

1 (2.5)
13 (32.5)
16 (40.0)
7 (17.5)
2 (5.0)
29.4 (8.3)

8 (66.7)
4 (33.3)

1 (50.0)
1 (50.0)

27 (67.5)
13 (32.5)

34 (85.0)
6 (15.0)

8 (66.7)
3 (25.0)
1 (8.3)
0 (0.0)

0 (0.0)
0 (0.0)
1 (50.0)
1 (50.0)

22 (55.0)
12 (30.0)
4 (10.0)
2 (5.0)

17 (42.5)
16 (40.0)
5 (12.5)
2 (5.0)

1 (8.3)
3 (25.0)
6 (50.0)
3 (25.0)
3 (25.0)

0 (0.0)
0 (0.0)
1 (50.0)
1 (50.0)
0 (0.0)

2 (5.0)
6 (15.0)
17 (42.5)
15 (37.5)
19 (47.5)

2 (5.0)
7 (17.5)
9 (22.5)
22 (55.0)
11 (27.5)

Charlson Cormorbidity Index
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Table 1.2. Breast cancer patients who experienced adverse events during or after cancer
therapy

Treatment modalitya
Surgery
n (%)
AA/B SCT+ (n=12)
No. received
Any AE
Potential sickling-related AE
AA/B SCT- (n=40)
No. received
Any AE
Potential sickling-related AE
NHW SCT- (n=40)
No. received
Any AE
Potential sickling-related AE

Radiation
n (%)

Chemotherapy
n (%)

12 (100)
7 (58.3)
1 (8.3)

6 (50.0)
5 (83.3)
0 (0.0)

8 (66.7)
6 (75.0)
4 (50.0)

38 (95.0)
12 (31.6)
2 (5.3)

29 (72.5)
11 (37.9)
0 (0.0)

29 (72.5)
17 (58.6)
3 (10.3)

38 (95.0)
6 (15.8)
0 (0.0)

25 (62.5)
3 (12.0)
0 (0.0)

22 (55.0)
7 (31.8)
1 (4.5)

AE: adverse event; SCT: sickle-cell trait
a

Patients who received more than one modality are counted in each category
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Table 2.1. SEER-Medicare data files83
File Name

Years
Included

File Summary

Diagnosis/Procedure
Codes

Patient entitlement
and diagnosis
summary file
(PEDSF)

2007-2013

• SEER data

SEER coding

Summarized
denominator file for
non-cancer cases
(SUMDENOM)

2006-2014

• Medicare HMO and
entitlement (month/year)
• 5% random sample of
Medicare beneficiaries
residing in SEER areas
without a diagnosis of cancer

None

• Medicare HMO and
entitlement (month/year)
Medicare analysis
and procedure file
(MEDPAR)

2006-2014

Outpatient

2006-2014

• Part A coverage
• 100% Medicare
hospitalizations with one
record per hospitalization
• Part B coverage
• 100% Medicare outpatient
claims with multiple
procedures for the same date
of service

Carrier Physician/supplier
(NCH)

2006-2014

Hospice

2006-2014

• Part B coverage
• 100% Physician/Provider
claims for single date of
service
• Part B coverage
• 100% of claims for one or
more dates

Home Health
Agency (HHA)

2006-2014

• Part A/Part B coverage
• 100% of claims for one or
more dates

74

ICD-9 diagnosis and
HCPCS† procedures

HCPCS and revenue
center procedures

ICD-9 diagnosis and
HCPCS procedures

ICD-9 diagnosis
codes

ICD-9 diagnosis
codes

†

File Name

Years
Included

File Summary

Diagnosis/Procedure
Codes

Durable Medical
Equipment (DME)

2006-2014

• Part B coverage

ICD-9 diagnosis and
HCPCS codes

• 100% of claims for one or
more dates

HCPCS: Health Care Common Procedure Classification System
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Table 2.2. Hemoglobinopathy Codes used to Identify Diagnosed Patients
Disorder/Variant
Thalassemia
Sickle-cell beta thalassemia

ICD-9
282.4
282.41
282.42

Alpha thalassemia

282.43

Beta thalassemia

282.44

Delta-beta thalassemia

282.45

Beta thalassemia trait

282.46

Hemoglobin E-beta thalassemia

282.47

Other thalassemia variants

282.49

Sickle-cell trait

282.5

Sickle-cell disease

282.6
282.61

Other sickle-cell variants

282.62
282.63
282.64

Sickle-cell anemia without crisis

282.68

Sickle-cell anemia with crisis

282.69

Other hemoglobinopathies

282.7

Hemoglobin C disease

282.7

Hemoglobin E disease

282.7
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Table 3.1. Demographic and clinicopathological characteristics by study group
Total
(n = 162,537)
n
%
Median Follow-up time
(months), IQR
Tumor site
Breast (female only)
Prostate
Age
66-74
75 to 84
≥85
Year of diagnosis
2007
2008
2009
2010
2011
2012
2013
SEER Registry Area
Northeast
Midwest
South
West
Urban/Rural Residence
Metro
Nonmetro
Median Household Income ($),
IQR
Median % Without HS
Education, IQR

AA/B+
(n = 371)
n

AA/B(n = 17,303)
n
%

%

NHW(n = 144,863)
n
%

p-valuec

56

35 - 80

52

33 - 78

53

32 - 77

57

35 - 80

<.001

75,633
86,904

46.53
53.47

187
184

50.40
49.60

6,732
10,571

38.91
61.09

68,714
76,149

47.43
52.57

<.001

89,954
55,910
16,673

55.34
34.40
10.26

233
106
32

62.80
28.57
8.63

10,554
5,335
1,414

61.00
30.83
8.17

79,167
50,469
15,227

54.65
34.84
10.51

<.001

26,794
25,163
23,852
23,199
23,285
20,379
19,865

16.48
15.48
14.67
14.27
14.33
12.54
12.22

64
47
57
45
70
39
49

17.25
12.67
15.36
12.13
18.87
10.51
13.21

2,723
2,650
2,591
2,509
2,480
2,269
2,081

15.74
15.32
14.97
14.50
14.33
13.11
12.03

24,007
22,466
21,204
20,645
20,735
18,071
17,735

16.57
15.51
14.64
14.25
14.31
12.47
12.24

.017

34,750
20,769
45,492
61,526

21.38
12.78
27.99
37.85

72
76
146
77

19.41
20.49
39.35
20.75

3,471
2,599
8,007
3,226

20.06
15.02
46.28
18.64

31,207
18,094
37,339
58,223

21.54
12.49
25.78
40.19

<.001

133,473
29,064

82.12
17.88

329
42

88.68
11.32

15,183
2,120

87.75
12.25

117,961
26,902

81.43
18.57

<.001

59,701

43.1 - 82.4

39,289

27.2 - 54.2

40,415

28.5 - 56.7

61,701

45.5 - 84.6

<.001

8.97 4.92 - 15.63

<.001

9.95 5.37 - 18.17

20.25 12.15 - 27.15
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18.28 11.06 - 26.16

Table 3.1 (con’t).
Total
(n = 162,537)
n
%
Marital Status
Married
Not married
Other
Charlson Comorbidity Score
0
1-2
≥3
AJCC Stage
0
I
II
III
IV
Unknown
Number of positive lymph
0
1-3
>4
No nodes examined
Unknown

AA/B+
(n = 371)
n

%

AA/B(n = 17,303)
n
%

NHW(n = 144,863)
n
%

p-valuec

88,895
57,235
16,407

54.69
35.21
10.09

150
180
41

40.43
48.52
11.05

6,903
8,246
1,974

39.89
47.66
11.41

81,842
48,629
14,392

56.50
33.57
9.93

<.001

71,354
55,175
18,334

43.90
33.95
11.28

85
150
136

22.91
40.43
36.66

6,467
6,861
3,975

37.38
39.65
22.97

71,354
55,175
18,334

49.26
38.09
12.66

<.001

11,811
31,473
87,111
10,735
10,903
10,504

7.27
19.36
53.59
6.60
6.71
6.46

34
67
190
21
37
22

9.16
18.06
51.21
5.66
9.97
5.93

1,157
2,125
10,242
1,073
1,507
1,199

6.69
12.28
59.19
6.20
8.71
6.93

10,620
29,281
76,679
9,641
9,359
9,283

7.33
20.21
52.93
6.66
6.46
6.41

<.001

49,746
9,723
4,184
94,427
4,457

30.61
5.98
2.57
58.10
2.74

108
19
13
215
16

29.11
5.12
3.50
57.95
4.31

3,834
991
475
11,445
558

22.16
5.73
2.75
66.14
3.22

45,804
8,713
3,696
82,767
3,883

31.62
6.01
2.55
57.13
2.68

<.001
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Table 3.1 (con’t).
Total
(n = 162,537)
n
%
Tumor characteristics breast
Tumor Size (cm)a
0-2
2.1-3
≥4
Unknown
Histologya
Ductal
Lobular
Other
Gradea
Well differentiated (1)
Moderately differentiated (2)
Poorly differentiated (3)
Undifferentiated (4)
Unknown
Estrogen Receptor Status a
Positive
Negative
Unknown
Progesterone Receptor Status a
Positive
Negative
Unknown

AA/B+
(n = 371)
n

%

AA/B(n = 17,303)
n
%

NHW(n = 144,863)
n
%

p-valuec

41,715
22,274
4,510
7,134

55.15
29.45
5.96
9.43

91
64
17
15

48.66
34.22
9.09
8.02

3,060
2,226
639
807

45.45
33.07
9.49
11.99

38,564
19,984
3,854
6,312

56.12
29.08
5.61
9.19

<.001

61,831
7,931
5,871

81.75
10.49
7.76

160
11
16

85.56
5.88
8.56

5,526
584
622

82.09
8.67
9.24

56,145
7,336
5,233

81.71
10.68
7.62

<.001

16,800
30,735
19,171
933
7,994

22.21
40.64
25.35
1.23
10.57

30
62
65
n/ad
n/a

16.04
33.16
34.76
n/a
n/a

1,072
2,522
2,133
72
933

15.92
37.46
31.68
1.07
13.86

15,698
28,151
16,973
861
7,031

22.85
40.97
24.70
1.25
10.23

<.001

59,251
10,077
6,305

78.34
13.32
8.34

130
40
17

69.52
21.39
9.09

4,749
1,328
655

70.54
19.73
9.73

54,372
8,709
5,633

79.13
12.67
8.20

<.001

50,537
18,009
7,087

66.82
23.81
9.37

113
56
18

60.43
29.95
9.63

3,978
2,045
709

59.09
30.38
10.53

46,446
15,908
6,360

67.59
23.15
9.26

<.001
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Table 3.1 (con’t).
Total
(n = 162,537)
n
%
Tumor Characteristics prostate
Gleason Score b
Well-differentiated, 2-4
Moderately-differentiated, 5-7
Poorly-differentiated, 8-10
Unknown
Notes :

845
48,744
31,990
5,325

0.97
56.09
36.81
6.13

AA/B+
(n = 371)
n

n/a
103
63
n/a

%

AA/B(n = 17,303)
n
%

n/a
55.98
34.24
n/a

110
5,770
3,959
732

a

breast cancer only

b

prostate cancer only

c

Chi-square test for categorical data and Kruskal-Wallis one-way ANOVA for continuous variables

d

values n/a suppressed due to cell size n<11
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1.04
54.58
37.45
6.92

NHW(n = 144,863)
n
%

734
42,871
27,968
4,576

0.96
56.30
36.73
6.01

p-valuec

<.001

Table 3.2. Distribution of selected comorbidities in the Charlson Comorbidity Index (CCI) by study group

Selected comorbidities (yes)
Myocardial infarction*
Congestive heart failure*
Peripheral vascular disease
Cerebrovascular disease*
a
COPD*
Dementia
Paralysis
Diabetes*
Diabetes with sequelae*
Chronic renal failure*
Moderate-severe liver disease
Ulcers*
Connective tissue disorders*
AIDS

AA/B+
(n = 371)
n
%
11 2.96
77 20.75
42 11.32
67 18.06
88 23.72
10 2.70
d
n/a
n/a
206 55.53
82 22.10
94 25.34
n/a
n/a
13 3.50
23 6.20
n/a
n/a

AA/B(n = 17,303)
n
%
252 1.46
2,181 12.60
1,934 11.18
2,375 13.73
3,099 17.91
482 2.79
196 1.13
6,716 38.81
2,217 12.81
2,437 14.08
43 0.25
308 1.78
561 3.24
60 0.35

Notes:
*Statistically significant difference between AA/B+ vs. AA/Ba

Chronic obstructive pulmonary disease

b

Chi-square test

d

values n/a suppressed due to cell size n<11

81

NHW(n = 144,863)
n
%
1,767 1.22
11,547 7.97
10,880 7.51
17,041 11.76
24,467 16.89
2,384 1.65
643 0.44
35,231 24.32
8,785 6.06
10,182 7.03
231 0.16
1,672 1.15
4,364 3.01
74 0.05

b

p-value

<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
<.001
.019
<.001
<.001
<.001

AA/B+ vs. AA/Bp-value*
.018
<.001
.930
.017
.004
.917
.177
<.001
<.001
<.001
.336
.014
.002
.140

Table 3.3. Breast cancer treatment receipt characteristics by study group

Total
(n = 75,633)

AA/B+
(n = 187)

AA/B(n = 6,732)

n

n

NHW(n = 68,714)

Receipt of Breast Cancer
a

Treatment
Surgery
Breast-conserving surgery (BCS)
Mastectomy
No initial surgery
Radiation therapy (RT)
Yes
No
Receipt of chemotherapy
Yes
No
Combined therapy (yes)
BCS+RT
Mastectomy+RT
BCS+RT+Chemotherapy
Mastectomy+RT+Chemotherapy

n

%

%

n

%

42,545 56.25
22,617 29.90
10,471 13.84

89 47.59
63 33.69
35 18.72

3,084 45.81
2,196 32.62
1,452 21.57

39,372 57.30
20,358 29.63
8,984 13.07

<.001

37,300 49.32
38,333 50.68

83 44.39
104 55.61

2,777 41.25
3,955 58.75

34,440 50.12
34,274 49.88

<.001

19,849 26.24
55,784 73.76

58 31.02
129 68.98

2,017 29.96
4,715 70.04

17,774 25.87
50,940 74.13

<.001

31,287 41.37
4,203 5.56
6,915 9.14
2,392 3.16

63 33.69
12 6.42
15 8.02
n/a
n/a

2,194 32.59
384 5.70
533 7.92
208 3.09

29,030 42.25
3,807 5.54
6,367 9.27
2,180 3.17

<.001
.749
.001
.678

a

Treatment received within 9 months of diagnosis

b

%

b

p-value

Chi-square test
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Table 3.4. Prostate cancer treatment receipt characteristics by study group

Receipt of Prostate Cancer Treatment
Initial curative therapy
Yes
No
Prostatectomyb

Total
(n = 86,904)
n
%

AA/B+
(n = 184)
n

%

AA/B(n = 10,571)
n
%

NHW(n = 76,149)
n
%

p-valuec

a

Yes
No

61,760
25,144

71.07
28.93

129
55

70.11
29.89

7,136
3,435

67.51
32.49

54,495
21,654

71.56
28.44

<.001

16,561
70,343

19.06
80.94

25
159

13.59
86.41

1,291
9,280

12.21
87.79

15,245
60,904

20.02
79.98

<.001

39,638

45.61

81

44.02

4,872

46.09

34,685

45.55

47,266

54.39

103

55.98

5,699

53.91

41,464

54.45

.528

29,699
57,205

34.17
65.83

73
111

39.67
60.33

3,804
6,767

35.99
64.01

25,822
50,327

33.91
66.09

<.001

30,904

35.56

79

42.93

3,926

37.14

26,899

35.32

56,000

64.44

105

57.07

6,645

62.86

49,250

64.68

b

Radiation Therapy (RT)
Yes

No
Androgen Deprivation Therapy (ADT)b
Yes
No
Chemotherapy
Yes
No

b

a

Receipt of surgery, radiation, or ADT within 180 days of diagnosis
bTreatment received within 12 months of diagnosis
c

Chi-square test
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<.001

Table 3.5. Treatment completion for breast cancer patients by stage and study group

Completion of Breast Cancer
a

Treatment (yes)
Stage
I (n= 31,343)
II (n= 18,774)
III (n= 3,263)
IV (n= 4,145)
Total

Totala
(n = 71,078)
n
%
17,399
7,936
601
635
37,077

55.51
42.27
18.42
15.32
52.16

AA/B+
(n = 178)
n
%
34 50.75
11 22.92
n/a
n/a
n/a
n/a
79 44.38

a

AA/B(n = 6,287)
n
%
1,081
645
45
70
2,854

51.21
34.81
6.62
13.01
45.40

NHW(n = 64,613)
n
%
16,284
7,280
556
563
34,144

55.83
43.15
10.85
15.67
52.84

Number of breast cancer patients with sufficient stage at diagnosis information to be included in analysis of treatment completion

c

Chi-square test

84

p-valuec

<.001
<.001
.001
.278
<.001

Table 3.6. Treatment completion for prostate cancer patients by stage and study group

Completion of Prostate Cancer
a

Treatment (yes)
Stage
I (n= 52,519)
II (n= 25,676)
III (n= 2,141)
IV (n= 989)
Total

Totala
(n = 81,325)
n
%
49,797
10,906
1,344
694
62,741

94.82
42.48
62.77
0.70
77.15

AA/B+
(n = 169)
n
%
104 96.30
20 37.04
n/a
n/a
n/a
n/a
128 75.74

a

AA/B(n = 9,822)
n
%
6,309
884
85
79
7,357

92.08
33.47
43.37
59.40
74.90

NHW(n = 71,334)
n
%
43,384
10,002
1,258
612
55,256

Number of prostate patients with sufficient stage at diagnosis information to be included in analysis of treatment completion

c

Chi-square test
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95.23
43.52
64.75
71.92
77.46

p-valuec

<.001
<.001
<.001
.012
<.001

Table 3.7. Risk of incomplete treatment by study group and cancer site

Study group
All patients
NHWAA/BAA/B+
Breast cancer
NHWAA/BAA/B+
Prostate cancer
NHWAA/BAA/B+

Unadjusted
(95% CI)
RR

p-value

Adjusted
RR

a

(95% CI)

p-value

PS weighted
RR

b

(95% CI)

p-value

1.00
1.21
1.13

-1.19 - 1.23
1.00 - 1.27

-<.001
.049

1.00
1.11
1.05

-1.09 - 1.13
0.94 - 1.17

-<.001
.393

1.00
1.09
1.03

-1.06 - 1.13
0.89 - 1.18

-<.001
.737

1.00
1.16
1.19

-1.13 - 1.20
1.01 - 1.40

-<.001
.038

1.00
1.05
1.10

-1.03 - 1.08
0.96 - 1.27

-<.001
.159

1.00
1.01
1.00

-0.96 - 1.05
0.82 - 1.21

-.816
.974

1.00
1.22
1.07

-1.19 - 1.25
0.90 - 1.27

-<.001
.451

1.00
1.17
1.04

-1.14 - 1.20
0.89 - 1.21

-<.001
.627

1.00
1.17
1.14

-1.12 - 1.22
0.84 - 1.27

-<.001
.737

Note : Relative Risk (RR) estimated using modified Poisson regression with robust error variance
a

Adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, CCI score, stage, number of positive lymph nodes, adverse events after surgery or
chemotherapy; Prostate cancer model adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, CCI score, stage, number of positive lymph
nodes, adverse events after surgery or ADT
b

Further adjusted for adverse events 30 days after surgery or 180 days after chemotherapy
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Table 3.8. Adverse events by study group

TOTAL
Number of adverse events
0
1
2
≥3
Adverse event within 90 days of

Totala
(n = 135,036)
n
%
135,036

AA/B+
(n = 309)
n
%
309

AA/B(n = 13,563)
n
%
13,563

NHW(n = 121,164)
n
%
121,164

p-value

45,557
45,972
26,008
17,499

33.74
34.04
19.26
12.96

46
93
84
86

14.89
30.10
27.18
27.83

3,750
4,657
3,076
2,080

27.65
34.34
22.68
15.34

41,761
41,222
22,848
15,333

34.47
34.02
18.86
12.65

<.001

surgeryb
Yes
No
Adverse event within 180 days of

9,969
71,828

12.19
87.81

28
151

15.64
84.36

946
5,637

14.37
85.63

8,995
66,040

11.99
88.01

<.001

chemotherapy or ADTc
Yes
No
Adverse events known to be

10,171
41,375

19.73
80.27

34
104

24.64
75.36

1,373
4,731

22.49
77.51

8,764
36,540

19.34
80.66

<.001

associated with hemoglobinopathies d
Yes
No
Adverse events putatively

15,402
119,634

11.41
88.59

69
240

22.33
77.67

1,708
11,855

12.59
87.41

13,625
107,539

11.25
88.75

<.001

associated with hemoglobinopathies e
Yes
No
Adverse events associated with

19,083
115,953

14.13
85.87

78
231

25.24
74.76

2,200
11,363

16.22
83.78

16,805
104,359

13.87
86.13

<.001

34,467
100,569

25.52
74.48

126
183

40.78
59.22

4,010
9,553

29.57
70.43

30,331
90,833

25.03
74.97

<.001

64,165
70,871

47.52
52.48

176
133

56.96
43.04

7,116
6,447

52.47
47.53

56,873
64,291

46.94
53.06

<.001

chemotherapy toxicityf
Yes
No
Emergency room visit
Yes
No
a

n = 135,036 patients received treatment (any surgery, any radiation, any chemotherapy, ADT)

b
c

n = 81,797 patients received surgery

n = 51,546 patients received chemotherapy or ADT

d

Hematuria, renal papillary necrosis, acute chest syndrome, anemia, myocardial infarction, thrombocytopenia, hyposthenuria, deep vein thromboembolism, splenic
infarction, rhabdommyolysis, hyphema, priapism, leg ulcers, cholelithiasis, stroke
e

Neutropenia, shortness of breath, pain, hemiplegia, renal toxicity, hepatic toxicity, hemolysis, organ failure, respiratory dysfunction/dyspnea

f

Infection, fever, mailaise, leukopenia, fracture, pulmonary, cardiac events, blood transfusion, hypercholesterolemia, nephritis, adverse events of antineoplastic and
immunosuppressive drugs
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Table 3.9. Risk of one or more adverse event requiring hospitalization or emergency room visits

Study group
All patients
NHWAA/BAA/B+
AA/B+ vs. AA/BBreast cancer
NHWAA/BAA/B+
AA/B+ vs. AA/BProstate cancer
NHWAA/BAA/B+
AA/B+ vs. AA/B-

Unadjusted
(95% CI)
RR

p-value

Adjusted
RR

(95% CI)

a

p-value

PS weighted
(95% CI)
RR

p-value

1.00
1.10
1.30
1.18

-1.09 - 1.12
1.24 - 1.36
1.12 - 1.23

-<.001
<.001
<.001

1.00
1.03
1.16
1.12

-1.02 - 1.05
1.11 - 1.22
1.07 - 1.18

-<.001
<.001
<.001

1.00
1.03
1.23
1.19

-1.01 - 1.06
1.15 - 1.31
1.11 - 1.27

-<.001
<.001
<.001

1.00
1.11
1.29
1.16

-1.09 - 1.13
1.22 - 1.38
1.09 - 1.24

-<.001
<.001
<.001

1.00
1.02
1.14
1.12

-0.99 - 1.03
1.07 - 1.22
1.05 - 1.20

-.061
<.001
<.001

1.00
1.02
1.20
1.17

-0.99 - 1.05
1.08 - 1.33
1.06 - 1.30

-0.12
<.001
.002

1.00
1.10
1.30
1.19

-1.08 - 1.12
1.21 - 1.40
1.10 - 1.27

-<.001
<.001
<.001

1.00
1.05
1.18
1.12

-1.04 - 1.07
1.10 - 1.26
1.04 - 1.20

-<.001
<.001
.002

1.00
1.04
1.25
1.20

-1.01 - 1.07
1.14 - 1.36
1.10 - 1.30

-<.001
<.001
<.001

Note : Relative Risk (RR) estimated using modified Poisson regression with robust error variance
a

Adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, education, CCI score, stage,
number of positive lymph nodes
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Table 3.10. Risk of one or more adverse event requiring hospitalization or emergency room visit among patients who
completed treatment

Study group
All patients
NHWAA/BAA/B+
AA/B+ vs. AA/BBreast cancer
NHWAA/BAA/B+
AA/B+ vs. AA/BProstate cancer
NHWAA/BAA/B+
AA/B+ vs. AA/B-

Unadjusted
RR

(95% CI)

p-value

1.00
1.11
1.35
1.21

-1.09 - 1.13
1.26 - 1.45
1.13 - 1.30

-<.001
<.001
<.001

1.00
1.10
1.35
1.22

-1.08 - 1.13
1.21 - 1.49
1.10 - 1.35

1.00
1.11
1.35
1.22

-1.09 - 1.14
1.24 - 1.48
1.11 - 1.34

Adjusted

PS weighted
(95% CI)
RR

(95% CI)

p-value

1.00
1.03
1.19
1.16

-1.01 - 1.05
1.11 - 1.28
1.08 - 1.24

-.001
<.001
<.001

1.00
1.03
1.21
1.17

-1.00 - 1.05
1.10 - 1.33
1.07 - 1.29

-.041
<.001
<.001

-<.001
<.001
<.001

1.00
1.01
1.18
1.17

-0.98 - 1.04
1.06 - 1.32
1.05 - 1.31

-.568
.002
.004

1.00
1.01
1.18
1.17

-0.96 - 1.05
0.98 - 1.42
0.97 - 1.41

-.721
.084
.098

-<.001
<.001
<.001

1.00
1.05
1.20
1.14

-1.03 - 1.07
1.10 - 1.31
1.04 - 1.25

-<.001
<.001
.003

1.00
1.04
1.22
1.17

-1.01 - 1.07
1.09 - 1.36
1.06 - 1.31

-.020
<.001
.003

RR

a

Note : Relative Risk (RR) estimated using modified Poisson regression with robust error variance
a

Adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, education, CCI score, stage,
number of positive lymph nodes

89

p-value

Table 3.11. Risk of one or more adverse event requiring hospitalization or emergency room visit among patients who did not
complete treatment

Study group
All patients
NHWAA/BAA/B+
AA/B+ vs. AA/BBreast cancer
NHWAA/BAA/B+
AA/B+ vs. AA/BProstate cancer
NHWAA/BAA/B+
AA/B+ vs. AA/B-

Unadjusted
RR

(95% CI)

p-value

1.00
1.07
1.24
1.15

-1.06 - 1.09
1.16 - 1.32
1.07 - 1.23

-<.001
<.001
<.001

1.00
1.09
1.20
1.10

-1.07 - 1.11
1.11 - 1.30
1.01 - 1.19

1.00
1.06
1.31
1.24

-1.03 - 1.09
1.17 - 1.47
1.10 - 1.39

Adjusted

PS weighted
(95% CI)
RR

(95% CI)

p-value

1.00
1.01
1.12
1.11

-1.00 - 1.03
1.05 - 1.20
1.03 - 1.18

-.159
.004
.004

1.00
1.00
1.13
1.14

-0.96 - 1.02
1.02 - 1.25
1.02 - 1.29

-.487
.009
.016

-<.001
<.001
.025

1.00
1.01
1.09
1.08

-0.99 - 1.03
1.00 - 1.19
0.99 - 1.18

-.192
.040
.084

1.00
1.01
1.14
1.13

-0.97 - 1.04
1.01 - 1.26
1.02 - 1.25

-.721
.018
.024

-<.001
<.001
<.001

1.00
1.02
1.18
1.15

-0.99 - 1.05
1.06 - 1.31
1.03 - 1.28

-.123
.002
.009

1.00
0.96
1.11
1.15

-0.91 - 1.01
0.89 - 1.38
0.93 - 1.44

-.137
.348
.190

RR

a

Note : Relative Risk (RR) estimated using modified Poisson regression with robust error variance
a

Adjusted for age, year of diagnosis, SEER region, metro residence, maritial status, income, education, CCI score, stage,
number of positive lymph nodes
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p-value

Table 3.12. Survival characteristics by study group and cancer site.

Outcome
Breast cancer
Survival, median (IQR), months
Vital status
Alive
Dead
Cause of death
Breast cancer
Other/unknown

AA/B+
(n = 371)
n
%

AA/B(n = 17,303)
n
%

52

(33 - 78)

130
57

69.52
30.48

4,281
2,451

63.59
36.41

17
40

29.82
70.18

886
1,565

36.02
63.62

2-year survival, % (95% CI)
5-year survival, % (95% CI)
Prostate cancer
Survival, median (IQR), months
Vital status
Alive
Dead
Cause of death
Prostate cancer
Other/unknown

89.89 (84.43 - 93.51)
75.85 (68.13 - 81.94)

2-year survival, % (95% CI)
5-year survival, % (95% CI)

87.43 (81.54 - 91.54)
67.95 (59.78 - 74.81)

47

(29 - 72)

87.71 (86.88 - 88.50)
69.04 (67.76 - 70.29)

52

(34 - 77.5)

55

(34 - 79)

109
75

59.24
40.76

7,261
3,310

68.69
31.31

17
58

22.67
77.33

738
2,572

22.30
77.70

90.06 (89.46 - 90.62)
74.59 (73.66 - 75.49)
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NHW(n = 144,863)
n
%
53

p -value

(33 - 77)

<.001

49,484
19,230

72.01
27.99

<.001

5,447
13,783

28.33
71.67

<.001

91.65 (91.44 - 91.86)
77.01 (76.65 - 77.36)
59

<.001
<.001

(38 - 82)

<.001

56,642
19,507

74.38
25.62

<.001

4,201
15,306

21.54
78.46

<.001

92.74 (92.55 - 92.93)
79.90 (79.56 - 80.21)

<.001
<.001

Figures
Figure 1.1. Proportion of breast cancer patients experiencing any complications/adverse events or potential sickling adverse
event following treatment (surgery, radiation, or chemotherapy).
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Figure 1.2. Conceptual Model
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Figure 3.1. Distribution of comorbidities by study group
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Figure 3.2. Distribution of Adverse Events (AEs) by category and study group

*Pairwise comparisons between AA/B+ vs. AA/B- and NHW-, respectively, p <.001
**Pairwise comparison between AA/B+ vs. AA/B-, p =.065; between AA/B+ vs. NHW-, p <.001
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Figure 3.3. Kaplan-Meier all-cause (top row), breast-cancer specific (middle row) and competing risk
(bottom row) survival curves by study group for unadjusted (left panels) and propensity score weighted
(right panels) breast cancer patients.

96

Figure 3.4. Kaplan-Meier all-cause (top row), prostate-cancer specific (middle row) and competing risk
(bottom row) survival curves by study group for unadjusted (left panels) and propensity score weighted
(right panels) prostate cancer patients.
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Figure 3.5. Propensity score weighted hazard ratios (HRs) for death among breast and
prostate cancer patients who failed to complete treatment by study group.
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Figure 3.6. Propensity score weighted hazard ratios (HRs) for death among breast and
prostate cancer patients who experienced one or more adverse event by study group.
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Figure 4.1. Risk of one or more adverse event requiring hospitalization or emergency room
visit by CCI Score.
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Figure 4.2. Propensity score weighted hazard ratios (HRs) for death among breast and
prostate cancer patients who experienced one or more adverse event by treatment
completion status and study group.
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Appendices
Appendix A1. Cohort Selection Criteria – Breast Cancer
246,524
Diagnosed with female breast
cancer 2007-2013
Exclude

n = 18,061
(7.3%)

228,463
First or only primary tumor
Exclude

n = 1,635
(0.72%)

Exclude

n = 88,381
(39.0%)

Exclude

n = 1,765
(1.3%)

226,828
Histology consistent with
epithelial origin

138,447
Age at diagnosis ≥66

136,682
Known month of diagnosis, not
diagnosed at death or autopsy
Exclude

n = 51,455
(37.7%)

85,227
Continuous AB/non-HMO
coverage from 1 year before to
1 year after diagnosis
Exclude

n = 296
(0.35%)

84,931
Not diagnosed with other cancer
in the year after diagnosis
n = 8,796
(10.4%)

Exclude

6,919
African American/Black

187
hemo+

69,216
Non-Hispanic White

6,732
hemo-

68,714
hemo-
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Exclude

n = 502
(0.66%)

Appendix A2. Cohort Selection Criteria – Prostate Cancer
278,955
Diagnosed with prostate cancer
2007-2013
Exclude

n = 6,327
(2.27%)

272,628
First or only primary tumor
Exclude

n = 1,057
(0.39%)

Exclude

n = 96,163
(35.41%)

Exclude

n = 3,981
(2.27%)

271,571
Histology consistent with
adenocarcinoma

175,408
Age at diagnosis ≥66

171,427
Known month of diagnosis, not
diagnosed at death or autopsy
Exclude

n = 69,508
(40.55%)

101,919
Continuous AB/non-HMO
coverage from 1 year before to
1 year after diagnosis
Exclude

n = 166
(0.16%)

101,753
Not diagnosed with other cancer
in the year after diagnosis
n = 14,356
(14.11%)

Exclude

10,755
African American/Black

184
hemo+

76,642
Non-Hispanic White

10,571
hemo-

76,149
hemo-
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Exclude

n = 493
(0.56%)

Appendix B1. Diagnosis and Treatment Codes – Breast cancer
Healthcare Common
Procedure Coding System

International Classification
of Diseases, 9th revision

Diagnosis
Malignant neoplasm of
female breast

174.0 - 174.9
C500 – C509 (ICD-O-3)
26000 (ICD-O-3 recode)

Surgery
Mastectomy

19180, 19182, 19200, 19220, 85.41, 85.42, 85.43, 85.44,
19240, 19303, 19304, 19305, 85.45, 85.46, 85.47, 85.48
19306, 19307

Breast-conserving surgery

19110, 19120, 19125, 19126, 85.20, 85.21, 85.22, 85.23,
19160, 19162, 19301, 19302 85.25

Radiation
External beam
radiotherapy

77402, 77403, 77404, 77406, V58.0, V67.1
77407, 77408, 77409, 77411, (administration)
77412, 77413, 77414, 77416

Intensity modulated
radiotherapy

77301, 77418, 0073T,
G0174

Brachytherapy

77761, 77762, 77763, 77776,
77777, 77778, 77781, 77782,
77783, 77784, 77799,
0182T, 19296, 19297,
19298, C9714, C9715

Chemotherapy
Agents & administration

J9000-J9999, J0640, J8530,
J8600, J8610, J8999, J8510,
J8520, J8521, 96400-96549,
Q0083-Q0085
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992.5, V58.1, V66.2, V67.2,
V07.51
(CEN: 0331, 0332, and
0335)

Appendix B2. Diagnosis and Treatment Codes – Prostate cancer
Healthcare Common Procedure
Coding System

International
Classification of Diseases,
9th revision

Diagnosis
Malignant neoplasm of prostate

185.0
C619 (ICD-O-3)
28010 (ICD-O-3 recode)

Surgery
Prostatectomy

55801, 55810, 55812, 55815,
55821, 55831, 55840, 55842,
55845

Laparoscopic Radical
Prostatectomy (robotic
assistance)

55866

60.3, 60.4, 60.5, 60.62,
60.69, 60.61 (local excision
of lesion of prostate)

Radiation
External beam radiotherapy

77402, 77403, 77404, 77406,
77407, 77408, 77409, 77411,
77412, 77413, 77414, 77416

Intensity-modulated radiation
therapy

77301, 77418, 0073T, G0174

Image-guided radiation therapy

77421, 76950, 77014, 76370,
C9722

Brachytherapy

77326, 77328, 76873, 77776,
77777, 77778, 77781, 77782,
77783, 77784, 77799, G0256,
G0261,

Stereotactic Radiosurgery

G0251, G0339, G0340, 0082T,
77373

Proton beam radiation therapy

77520, 77522, 77523, 77525

Androgen Deprivation
Therapy
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92.21 – 92.29

Healthcare Common Procedure
Coding System

International
Classification of Diseases,
9th revision

orchiectomy

54520, 54521, 54522, 54535,
54690, 54530

62.4, 62.41, 62.42

Hormone therapy

49510, 11980, J9202 (goserelin),
J9217, J9218, J9219, J1950,
C9430, (leuprolide), J3315
(Triptorelin pamoate), C9216,
S0165, (Abarelix), S0175
(Flutamide), S9560

Chemotherapy
Agents & administration

J9000-J9999, J0640, J8530, J8600,
J8610, J8999, J8510, J8520,
J8521, 96400-96549, Q0083Q0085
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992.5, V58.1, V66.2,
V67.2, V07.51
(CEN: 0331, 0332, and
0335)

Appendix B3. Adverse Event Codes
Adverse Event

ICD-9 Code

Anemia

281, 283, 284, 285

Thrombocytopenia

287.4, 287.5

Leukopenia

288.5

Neutropenia

288.0

Infections/fever

001.0–139.8, 780.6, 99.85

Dehydration

276.5

Nausea/vomiting/diarrhea/fatigue/headache

780.0, 780.52, 787.0, 787.91,
564.5, 780.4, 784.0, 346

Renal toxicity, renal failure (including chronic kidney
disease)

403.01, 403.11, 403.91, 404.02,
404.03, 404.12, 404.13, 404.92,
404.93, 588.0, V42.0, V45.1,
583.6, 585, 586, V56, 584

Deep vein thrombosis

444, 445, 451, 452, 453

Pulmonary embolism

415

Other pulmonary conditions

416-417, 518.0–518.89

Emergency Room (ER) visit

99281 – 99285 (HCPCS)

Adverse effect of systemic therapy

E933.1

Shortness of breath

786.05

Severe chest pain

786.5

Diffuse body aches, severe back pain, myalgia,
artharalgia

724.8, 729.10, 729.1, 719.4

Hemiplegia

342

Hepatic toxicity

573.9, 572.8, 570, 573.3

Hemolysis

283

Multiorgan failure

995.94

Respiratory distress/dyspnea

518.81, 786.0

Hypoxia

799.02
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Adverse Event

ICD-9 Code

Mechanical ventilation

96.7

Vaso-occlusive crisis

282.62

Mucositis

528.0, 112.0, 101

Hematuria

599.7

Renal papillary necrosis

584.7

Acute chest syndrome

517.3

Hyposthenuria

593.89

Splenic infarction

289.59

Rhabdomyolysis

728.88

Complicated hyphema

364.41

Priapism

607.3

Leg ulcers

707.25

Gallstones/cholelithiasis, cholecystitis

574, 575

Stroke

433-435

Myocardial infarction

410.0-413.9

Blood transfusion

V58.2, 99.03, 99.04

Cardiomyopathy/hypertension/heart failure

398.91, 401.0-4.05.9, 422.90,
425.4, 425.9, 428

Unspecified diseases of blood and blood-forming organs

289.9

108

Appendix C. Propensity Score Weighting and Balance Diagnostics
###########################################################################################################
library(twang)
library(survey)
#BREAST
set.seed(1)
bmnps <- mnps(hemo_cat ~ agecat + YRDX1 + mar_cat + seer_reg + stage + ln_pos + PCHRLSON + income_q +
hs_q + breast_grade + breast_hist + her2 + estrogen + progesterone + t_size,
data = breast1,
estimand = "ATE",
verbose = FALSE,
stop.method = c("es.mean","ks.mean"),
n.trees = 10000)
plot(bmnps, plots=1, subset = "es.mean")
plot(bmnps, plots=2, subset = "es.mean")
plot(bmnps, plots=3, subset = "es.mean")
#export summary table of balance diagnostics
breastBT <- as.data.frame(bal.table(bmnps, es.cutoff = 0.1))
write.csv(breastBT, file = "breastBT.csv")
#get weights and export to .csv
breast1$w <- get.weights(bmnps,stop.method = "es.mean")
write.csv(breast1, file = "bmnps.csv")
###########################################################################################################
#PROSTATE
set.seed(1)
pmnps <- mnps(hemo_cat ~ agecat + YRDX1 + mar_cat + seer_reg + stage + ln_pos + PCHRLSON + income_q +
hs_q + gleason + pros_stg,
data=prostate1,
estimand="ATE",
verbose = FALSE,
stop.method = c("es.mean","ks.mean"),
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n.trees = 10000)
plot(pmnps, plots=1, subset = "es.mean")
plot(pmnps, plots=2, subset = "es.mean")
plot(pmnps, plots=3, subset = "es.mean")
#export summary table of balance diagnostics
prosBT <- as.data.frame(bal.table(pmnps, es.cutoff = 0.1))
write.csv(prosBT, file = "prostateBT.csv")
#get weights and export to .csv
prostate1$w <- get.weights(pmnps,stop.method = "es.mean")
write.csv(prostate1, file = "pmnps.csv")
###########################################################################################################
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Figure C1. Summarized absolute standardized mean difference (ASMD) after 10,000 generalized boosted regression (GBM)
model iterations for breast (left) and prostate (right) samples.
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Figure C2. ASMD plots assessing maximum pairwise covariate balance after weighting by study group for breast (left) and
prostate (right) samples.
Note: solid circle indicates statistically significant difference between unweighted and weighted ASMD.
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Figure C3. Box plots of estimated propensity score overlap by study group for breast (left) and prostate (right) samples.
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Table C1a. Maximum ASMD and minimum p-values remained >.10 across all pairwise
comparisons for each covariate after weighting, breast cancer sample.
Group 1
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+

Group 2
AA/BAA/BAA/BAA/BAA/BAA/BAA/BAA/BAA/BAA/BAA/BAA/BAA/BNHWNHWNHWNHWNHWNHWNHWNHWNHWNHWNHWNHWNHWNHW-

variable
agecat:1
agecat:3
YRDX1:2010
YRDX1:2013
mar_cat:1
mar_cat:2
seer_reg:4
income_q:1
hs_q:1
hs_q:5
hs_q:6
breast_grade:4
her2:1
agecat:1
agecat:3
YRDX1:2010
YRDX1:2013
mar_cat:1
mar_cat:2
seer_reg:4
income_q:1
income_q:5
hs_q:1
hs_q:5
hs_q:6
breast_grade:4
her2:1

mean1
0.595
0.081
0.104
0.19
0.29
0.665
0.228
0.444
0.083
0.39
0
0
0.019
0.595
0.081
0.104
0.19
0.29
0.665
0.228
0.444
0.092
0.083
0.39
0
0
0.019
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mean2
0.505
0.129
0.14
0.14
0.343
0.601
0.294
0.34
0.127
0.305
0
0.011
0.055
0.504
0.132
0.14
0.136
0.354
0.591
0.309
0.317
0.137
0.139
0.288
0
0.012
0.053

pop.sd std.eff.sz
0.5
0.181
0.34
0.143
0.347
0.104
0.346
0.142
0.477
0.11
0.491
0.13
0.459
0.143
0.471
0.221
0.344
0.129
0.455
0.188
0
NA
0.107
0.102
0.224
0.164
0.5
0.182
0.34
0.15
0.347
0.105
0.346
0.154
0.477
0.134
0.491
0.151
0.459
0.177
0.471
0.27
0.341
0.132
0.344
0.165
0.455
0.224
0
NA
0.107
0.109
0.224
0.155

p
stop.method
0.100
es.mean
0.100
es.mean
0.718
es.mean
0.718
es.mean
0.297
es.mean
0.297
es.mean
0.456
es.mean
0.391
es.mean
NA
es.mean
NA
es.mean
NA
es.mean
0.423
es.mean
0.056
es.mean
0.090
es.mean
0.090
es.mean
0.696
es.mean
0.696
es.mean
0.201
es.mean
0.201
es.mean
0.275
es.mean
0.185
es.mean
0.185
es.mean
NA
es.mean
NA
es.mean
NA
es.mean
0.368
es.mean
0.067
es.mean

Table C1b. Maximum ASMD and minimum p-values remained >.10 across all pairwise
comparisons for each covariate after weighting, prostate cancer sample.
Group 1
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B+
AA/B-

Group 2
AA/BAA/BAA/BAA/BAA/BNHWNHWNHWNHWNHWNHWNHWNHW-

variable
seer_reg:3
seer_reg:4
stage:0
stage:99
hs_q:1
seer_reg:3
seer_reg:4
stage:0
stage:99
income_q:1
income_q:4
hs_q:1
stage:0

mean1
0.438
0.208
0
0.048
0.083
0.438
0.208
0
0.048
0.394
0.117
0.083
0

mean2
0.385
0.268
0
0.078
0.123
0.385
0.278
0
0.077
0.335
0.154
0.13
0
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pop.sd std.eff.sz
0.485
0.108
0.445
0.134
0
NA
0.269
0.109
0.334
0.12
0.485
0.109
0.445
0.155
0
NA
0.269
0.106
0.475
0.124
0.358
0.103
0.334
0.142
0
NA

p
stop.method
0.405
es.mean
0.405
es.mean
NA
es.mean
NA
es.mean
0.693
es.mean
0.311
es.mean
0.311
es.mean
NA
es.mean
NA
es.mean
0.638
es.mean
0.638
es.mean
0.531
es.mean
NA
es.mean

Appendix D. Select Sensitivity Analysis including NHW+ patients

Table D1. Frequency distribution for hemoglobinopathies in the SEER-Medicare study cohort
Total
(n = 163,532)

Disorder/Variant
Sickle Cell Trait
Sickle Cell Disease
Thalassemia
Other Hemoglobinopathies
Totala
a

AA/B
(n = 17,674)
n
%
137
0.78
89
0.50
94
0.53
96
0.54
371

2.10

Breast cancer
(n = 76,135)
AA/B
NHW
(n = 6,919)
(n = 69,216)
n
%
n
%
77
1.11
18
0.03
42
0.61
43
0.06
54
0.78
192
0.28
44
0.64
262
0.38

NHW
(n = 145,858)
n
%
40
0.03
85
0.06
371
0.25
520
0.36
995

0.68

187

Some patients diagnosed with ≥1 hemoglobinopathy variant
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2.70

502

0.73

Prostate cancer
(n= 87,397)
AA/B
NHW
(n= 10,755)
(n = 76,642)
n
%
n
%
60
0.56
22
0.03
47
0.44
42
0.05
40
0.37
179
0.23
52
0.48
258
0.34
184

1.71

493

0.64

Table D2. Prevalence of CCI Score by study group

CCI Score
0
1
2
3
4
5+
Total

AA/B+
n
%
85 22.9%
79 21.3%
71 19.1%
39 10.5%
36
9.7%
61 16.4%
371

AA/Bn
6,467
4,152
2,709
1,567
1,080
1,328
17,303

NHW-

%
37.4%
24.0%
15.7%
9.1%
6.2%
7.7%
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n
71,354
36,753
18,422
8,938
4,821
4,575
144,863

%
49.3%
25.4%
12.7%
6.2%
3.3%
3.2%

NHW+
n
408
259
145
64
60
59
995

%
41.0%
26.0%
14.6%
6.4%
6.0%
5.9%

Table D3. Incidence of adverse events requiring hospitalization
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